

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2)

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-020785
Article Type:	Protocol
Date Submitted by the Author:	23-Nov-2017
Complete List of Authors:	 Ai, Dashan; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Chen, Yun; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Liu, Qi; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhang, Junhua; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Department of Oncology Department of Oncology Deng, Jiaying; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Deng, Jiaying; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhu, Hanting; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Ren, Wenjia; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zheng, Xiangpeng; Huadong Hospital Affiliated to Fudan University, Department of Radiation Oncology Zheng, Xiangpeng; Huadong Hospital Affiliated to Fudan University, Department of Radiation Oncology Wei, Shihong; Gansu Province Cancer Hospital, Department of Radiation Oncology Ye, Jinjun; Jiangsu Cancer Hospital, Department of Radiation Oncology Lin, Qin; First Affiliated Hospital of Xiamen University, Department of Radiation Oncology Lin, Qin; First Affiliated Hospital of Xiamen University, Department of Radiation Oncology Lin, Hui; Jiangxi Province Cancer Hospital, Department of Radiation Oncology

2
3
4
5
ر د
6
7
8
9
10
10
11
12
13
14
1
15
16
17
18
10
12
20
21
22
23
23
24
25
26
27
20
20
29
30
31
32
22
33
34
35
36
20
37
38
39
40
41
40
42
43
44
45
16
40
47
48
49
50
50 F 1
51
52
53
54
55
22
56

57 58 59

60

Oncology Huang, Guang; Hainan Province People's Hospital, Department of Radiation Oncoloav Wu, Kailiang; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Fan, Min; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Yang, Huanjun; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhu, Zhengfei; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhao, Weixin; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Li, Ling; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Fan, Jianhong; Renhe Hospital, Department of Gynecology Badakhshi, Harun; Charite' School of Medicine and Centre for Cancer Medicine, Department of Radiation Oncology Zhao, Kuaile; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology esophageal squamous cell carcinoma, concurrent chemoradiotherapy, Keywords: paclitaxel, cisplatin, carboplatin, fluorouracil

> SCHOLARONE[™] Manuscripts

BMJ Open

Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2) Dashan Ai^{1, 2}, Yun Chen^{1, 2}, Qi Liu^{1, 2}, Junhua Zhang^{1, 2}, Jiaying Deng^{1, 2}, Hanting Zhu^{1, 2}, Wenjia Ren^{1, 2}, Xiangpeng Zheng³, Yunhai Li⁴, Shihong Wei⁵, Jinjun Ye⁶, Jialiang Zhou⁷, Qin Lin⁸, Hui Luo⁹, Jianzhong Cao¹⁰, Jiancheng Li¹¹, Guang Huang¹², Kailiang Wu^{1, 2}, Min Fan^{1, 2}, Huanjun Yang^{1, 2}, Zhengfei Zhu^{1, 2}, Weixin Zhao^{1, 2}, Ling Li^{1, 2}, Jianhong Fan¹³, Harun Badakhshi¹⁴, Kuaile Zhao^{1, 2} 1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China 3. Department of Radiation Oncology, Huadong Hospital Affiliated to Fudan University, Shanghai, China 4. Department of Radiation Oncology, Fudan University Shanghai Cancer Center Minhang Branch Hospital, Shanghai, China 5. Department of Radiation Oncology, Gansu Province Cancer Hospital, Lanzhou, China 6. Department of Radiation Oncology, Jiangsu Province Cancer Hospital, Nanjing, China 7. Department of Radiation Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China 8. Department of Radiation Oncology, First Affiliated Hospital of Xiamen University, Xiamen, China 9. Department of Radiation Oncology, Jiangxi Province Cancer Hospital, Nanchang, China 10. Department of Radiation Oncology, Shanxi Province Cancer Hospital, Taiyuan, China 11. Department of Thoracic Radiation Oncology, Fujian Province Cancer Hospital, Fuzhou, China 12. Department of Radiation Oncology, Hainan Province People's Hospital, Haikou, China For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

60

BMJ Open

1	
2	12 Department of Cymanology Depha hognital Shanghai China
4	15. Department of Gynecology, Kenne hospital, Shanghal, China
5	14. Department of Radiation Oncology, Charite' School of Medicine and Centre for
6 7	Cancer Medicine, Berlin, Germany
8	Corresponding author: Kuaile Zhao, 270 Dongan Rd, Shanghai, 200032, China, Email:
9	busile z@shee erz er Tel: 186 21 64175500
10 11	<u>kuane_2(ω/snca.org.cn</u> . 1et. +86-21-641/5590
12	Key words: esophageal squamous cell carcinoma, concurrent chemoradiotherapy,
13	paclitaxel, cisplatin, carboplatin, fluorouracil
14	Word counts: 2 316 words
15	Word County. 2,910 Words
17	
18	
19	
20	
22	
23	
24 25	
26	
27	
28	
29 30	
31	
32	
33	
35	
36	
37	
38 39	
40	
41	
42	
43	
45	
46	
47 48	
49	
50	
51	
52 53	
54	
55	
56 57	
58	2

Abstract

Introduction: Concurrent chemoradiation is the standard therapy for patients with local advanced esophageal carcinoma unsuitable for surgery. Paclitaxel is an active agent against esophageal cancer and it has been proved as a potent radiation sensitizer. There have been multiple studies evaluating paclitaxel-based chemoradiation in esophageal cancer, the results of which are inspiring. However, which regimen, among paclitaxel in combination with cisplatin (TP), carboplatin (TC) and fluorouracil (TF) concurrent with radiotherapy, provides best prognosis with minimum adverse events is still considered far from resolved and very few studies focus on this field. The purpose of this study is to confirm the priority of TF to TP or TC concurrent with radiotherapy in terms of overall survival and propose a feasible and effective plan for patients with local advanced esophageal cancer. Methods and analysis: ESO-Shanghai 2 is a three-arm, multicenter, open-labeled, randomized phase III clinical trial. The study was initiated in July 2015 and the duration of inclusion will be 4 years. The study compares two pairs of regimen: TF versus TP and TF versus TC concurrent with definitive radiotherapy for patients with esophageal squamous cell carcinoma (ESCC). Patients with histologically confirmed ESCC (clinical stage II, III or IVa based on the 6th UICC-TNM classification) and without any prior treatment of chemotherapy, radiotherapy or surgery against esophageal cancer will be eligible. A total of 321 patients will be randomized and allocated in a 1:1:1 ratio to the three treatment groups. Patients are stratified by lymph node status (N0, N1, M1a). The primary endpoint is overall survival and the secondary endpoint is progression-free survival and adverse events. Ethics and dissemination:

This trial has been approved by the Fudan University Shanghai Cancer Center Institutional Review Board. Trial results will be disseminated via peer reviewed scientific journals and conference presentations.

Trial registration: Clinicaltrials.gov: NCT02459457

Strengths and limitations of this study

- First phase III randomized multi-centered study comparing these three regimens
- Stratification by lymph node status (N0, N1, M1a based on the 6th UICC-TNM classification)

to peer teriew only

Introduction

Worldwide, esophageal cancer is the eighth most common cancer, which is responsible for an estimated 455,800 new cases and 400,200 deaths in 2012.¹ Since its prognosis is dismal, much effort has been put into improving overall survival through multi-modality treatments, which consist of surgery, radiotherapy and chemotherapy.² Concurrent chemoradiation is the standard non-operative therapy for local advanced esophageal squamous cell carcinoma (ESCC).³

Paclitaxel is an active agent against esophageal cancer, with the response rate of 28% in ESCC, and it has been shown to be a potent radiation sensitizer.⁴ There have been multiple studies evaluating paclitaxel-based chemoradiation in esophageal cancer, for instance, paclitaxel/fluorouracil (TF) developed at The University of Texas M.D. Anderson Cancer Center, and paclitaxel/cisplatin (TP) developed at Memorial Sloan-Kettering Cancer Center, ⁵⁶ with paclitaxel/carboplatin (TC) from CROSS trial.⁷ In many preoperative studies, paclitaxel-based chemoradiotherapy has achieved inspiring effect, the pathologic complete response rates of TP-based chemoradiotherapy were 19%-42%, ⁸⁻¹¹ and of TC-based chemoradiotherapy was 49%.⁷ However, which regimen, among TF, TP and TC-based definitive chemoradiotherapy, provides best prognosis with minimum adverse events is still considered far from resolved and very few studies focus on this field.

RTOG 0113⁵ evaluated 2 different paclitaxel-based regimens (TP and TF). Eighty-four patients were accrued to this study. Patients in arm A (TF) received induction 5-FU, cisplatin, and paclitaxel followed by radiation and concurrent continuous infusion 5-FU and weekly paclitaxel. Patients in arm B (TP) received induction paclitaxel and cisplatin followed by radiation and concurrent weekly cisplatin and 96-hour infusion of paclitaxel. The median survival time was 28.7 months for patients in arm A (TF) and 14.9 months for patients in arm B (TP). Neither arm achieved the hypothesized 1-year survival rate of at least 77.5%. The main deficiency of this study is the small sample size, but the effect of TF group is still inspiring.

Another perspective multicenter randomize clinical trials from Europe¹² showed the overall survival of TC-based definitive chemoradiotherapy was comparable with cisplatin/5-FU(PF) as definitive concurrent chemoradiotherapy in esophageal cancer.

BMJ Open

However, the toxicity rates were lower in the TC group together with higher treatment compliance.

Based on RTOG 0113 and other reports, we designed a multicenter randomized controlled phase III trial to confirm the priority of TF to TP and TF to TC concurrent with radiotherapy in terms of overall survival for patients with local advanced esophageal squamous cell carcinoma. Independent ethics committees of the participating centers approved the study protocol. This trial has been registered with ClinicalTrials.gov, number NCT02459457.

The trial is a three-arm, multicenter, open-labeled, randomized phase III clinical trial. The study was initiated in July 2015 and the duration of inclusion will be 4 years. The study compares two pairs of regimen: TF versus TP and TF versus TC concurrent with definitive radiotherapy in patients with esophageal squamous cell carcinoma.

Methods and analysis

Patient selection

To be eligible for this study, patient must fulfill all of the following criteria (Table 1):

Inclusion criteria

- 1. Histologically confirmed esophageal squamous cell carcinoma
- 2. Clinical stages II, III or IVa based on the 6th UICC-TNM classification
- 3. No prior treatment of chemotherapy, radiotherapy or surgery against esophageal cancer, except for non-curative resection by EMR/ESD.
- 4. Aged 18-75 years
- 5. Adequate organ functions for chemoradiation therapy
 - a) White blood cell (WBC) $\geq 3 \times 10^{9}$ /L
 - b) Absolute neutrophil counts (ANC) $\geq 1.5 \times 10^{9}/L$
 - c) Hemoglobin (Hb) $\geq 10g/dl$
 - d) Platelet (Plt) $\geq 100 \times 10^{9}$ /L
 - e) Total bilirubin <1.5 upper limit of normal (ULN)
 - f) Aspartate transaminase (AST) ≤ 2.5 ULN
 - g) Alanine aminotransferase (ALT) ≤ 2.5 ULN

- h) Creatinine ≤1.5 ULN
- 6. ECOG PS of 0-2
- 7. Life expectancy \geq 3 months
- 8. Written informed consent

Patients fulfilling any of the following criteria are ineligible for this study (Table 2).

Exclusion criteria

1. Esophageal perforation or hematemesis

2. Synchronous or metachronous malignancies (except for cutaneous (non-melanomas) carcinoma, thyroid papillary carcinoma, phase I seminoma or cervical carcinoma in situ curatively treated and disease free for a minimum of 3 months)

- 3. Received thoracic, abdominal or craniocerebral surgery within 30 days
- 4. Enrolled in other clinical trials within 30 days
- 5. Unstable angina and/or congestive heart failure requiring hospitalization within 6 months

6. Severe psychiatric disease

7. Pregnancy, lactation or unwillingness to adopt contraception

8. Drug addiction

9. Acquired immune deficiency syndrome (AIDS) based upon current CDC definition

- 10. History of radiotherapy in the planning area
- 11. Other ineligible conditions according to researchers

Treatment

The treatment plan is shown in Figure 1. Patients receive radiotherapy combined with concurrent chemotherapy. Radiotherapy begins on day 1, concurrent with the beginning of cycle 1 of chemotherapy.

Same radiation therapy will be delivered in all three treatment groups. Radiotherapy is delivered with photons (≥ 6 MV) to a total dose of 61.2Gy in 34 fractions. Patients will be treated 5 days per week at 1.8Gy/d. Three-dimensional conformal radiotherapy or intensity modulated radiotherapy is required. All patient will be positioned in an individualized immobilization device in the treatment

BMJ Open

position.

The definition of volumes will be in accordance with the 1993 ICRU Report #50 and 1999 ICRU Report #62.

The gross target volume (GTV) is defined as all known involved field, which detected by endoscopic ultrasound, barium swallow or CT scan (whichever is larger). The regional lymph nodes included in GTV is whose diameter more than 1cm (0.5cm for lymph nodes at tracheoesophageal groove) or histologically proven metastatic after puncture.

The superior and inferior borders of the clinical target volume (CTV) are 3cm beyond the primary tumor along the esophagus. The lateral, anterior and posterior borders of the field are the same as GTV.

The superior, inferior, anterior, posterior and lateral borders of planning target volume (PTV) are 1cm beyond CTV. Field next to the spinal cord could be slightly adjusted in order to reduce the exposure of spinal cord.

As for target volume, tissue inhomogeneity correction is adopted and it is required that more than 99% PTV receive 95% prescription dose and more than 95% PTV receive 99% or more prescription dose. Highest and lowest point dose inside PTV should be recorded.

When making the treatment plan, we should take normal organ dose restrictions into consideration as the following order: (Table 3)

Risk organ	Contour regulation	Dose restriction
Spinal cord	All the layers of CT scan have	Highest point dose less
	to be contoured and the margin	than 45Gy
	of vertebra tube can be	
	regarded as that of planning	
	organ at risk volume.	
Lung	It is allowed to use automatic	The volume of lung (PTV
	tools in the delineation of	excluded) receiving 20Gy
	margin of lungs. (Trachea and	or higher has to be less
	bronchia must be contoured	than 30% of the total lung
	manually)	volume, and the median

		dose has to be less than 15Gy.
Heart	The superior margin of heart	The median dose has to be
	consists of right atrium and	less than 40Gy.
	right ventricle, pulmonary	
	artery trunk, ascending main	
	aorta and superior vena cava	
	excluded. The inferior margin	
	is at the level of heart apex.	
Chemotherapy		
Patients are randomly	assigned to receive one of three the	rapies.
Arm A (TP)		
Patients in arm A recei	ive 4 courses of TP every 4 weeks. I	Details are as follows:
Paclitaxel: 175mg/m ² /	d, ivgtt over 3 hours, d1; Cisplatin:	25mg/m ² /d, ivgtt, d1-3;
Arm B (TF)		
Patients in arm B rec	eive 6 courses of TF concurrent w	ith radiotherapy every week
and 2 courses of TF ac	ljuvant chemotherapy every 4 week	s. Details are as follows:
Concurrent: paclitaxel	1 50mg/m ² /d, ivgtt over 3 hours, d1	; 5-FU 300mg/m ² , civ 96h
d1-4		
Adjuvant: paclitaxel 1	75 mg/m ² /d, ivgtt over 3 hours, d1	; 5-FU 1800mg/m ² , civ 72h
d1-3		
Arm C (TC)		
Patients in arm C rece	eive 6 courses of TC concurrent w	ith radiotherapy every weel
and 2 courses of TC a	djuvant chemotherapy every 4 week	s. Details are as follows:
Concurrent: paclitaxel	50mg/m ² /d, ivgtt over 3 hours, d1	; carboplatin AUC=2, ivgtt
d1		
Adjuvant: paclitaxel 1	75 mg/m ² /d, ivgtt over 3 hours, d1	; carboplatin AUC=5, ivgt
d1		
Patients receive prem	edication to prevent allergic reaction	on and significant nausea o
vomiting as indicated.		

Page 11 of 17

Dose modifications

Radiotherapy interruption

If following toxicity is observed, radiotherapy has to be delayed until toxicity is no more than grade 2.

- WBC< 2.0×10^9 /L or ANC< 1.0×10^9 /L
- Plt<50 \times 10⁹/L
- Grade 3 or higher non-hematological toxicity

If following toxicity is observed, radiotherapy has to be delayed until complete recovery.

• Mediastinal or thoracic infection with fever over 38.5

It is allowed to suspend at most 2 weeks, or radiotherapy will be terminated.

Chemotherapy interruption and dose modifications

If following toxicity is observed on day 1, chemotherapy has to be delayed until toxicity is no more than grade 1.

- ANC< $1.5 \times 10^{9}/L$
- $Plt < 100 \times 10^9/L$

• Grade 2 or higher non-hematological toxicity, except for nausea, vomiting and alopecia

It is allowed to delay at most 2 weeks, or chemotherapy will be terminated.

Chemotherapy dose modifications are based on the greatest toxicity during the last cycle. Any patients who need to make chemotherapy dose modifications will receive the modified dose in the following cycles.

If modifications are needed, dose of paclitaxel, cisplatin, carboplatin and 5-FU will decreased by 25% from the planned dose for the first time and 50% for the second time. It is allowed to make dose modifications at most twice, or chemotherapy will be terminated. Details are as follows:

Dose modification of paclitaxel

• Febrile neutropenia (ANC< 0.5×10^9 /L and fever over $38.3 \square$ or over $38.0 \square$ for 1h)

• Grade 2 or higher peripheral neuropathy

Dose modification of cisplatin and carboplatin

• Febrile neutropenia (ANC< 0.5×10^9 /L and fever over $38.3 \square$ or over $38.0 \square$ for 1h)

- Grade 2 or higher peripheral neuropathy
- Serum creatinine >3ULN

Dose modification of 5-FU

• Febrile neutropenia (ANC< 0.5×10^9 /L and fever over 38.3 \Box or over 38.0 \Box for

1h)

• Grade 3 or higher mucositis

The adverse events will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0). All adverse events, occurring during the course of the trial, which is from randomization until 28 days after end of treatment, regardless of relatedness to study medication, will be recorded. Adverse events occurring later than 28 days after the end of treatment will only be recorded if they are considered relevant.

Randomization

After the confirmation of eligibility criteria, patients will be randomly allocated in a 1:1:1 ratio to the three treatment groups by a central randomization center (Fudan University Shanghai Cancer Center, Shanghai, China). Patients will be stratified by lymph node status (N0, N1, M1a). The SAS was used to generate a random permutation sequence and produce patient randomization numbers. The data center registers the enrollment, assigns a unique identification number to every participant, and replies to the respective investigators.

Sample size calculation and statistical analysis

This three-arm randomized trial is designed to confirm whether TF is superior to TP or TC concurrent with radiotherapy in terms of overall survival. According to RTOG 0113 and other reports, median survival time of TF concurrent with radiotherapy for esophageal cancer is 28.7 months while TP 14.9 months⁵ and TC 17.4 months¹³. According to the Schoenfeld and Richter's method, the sample size of 107 patients per arm (154 events in total) is required to warrant a power of 80% at a two-sided α

BMJ Open

level of 0.025 for the comparison between TP and TF with relatively smaller difference, assuming an accrual period of 48 months, a minimum follow-up period of 24 months and a dropout rate of $10\%^{14}$ ¹⁵. The total sample size is planned as 321 patients (107 patients in each arm, a total of 231 events).

The median overall survival will be estimated with Kaplan-Meier method, and log-rank test will be used to compare the overall survival among treatment arms. We will conduct a subgroup analyze to test whether the treatment effects differ among subgroups (N0, N1, M1a).

Endpoints

The primary endpoint is overall survival in all randomized patients. Overall survival is defined as time from the date of randomization until death. The secondary endpoint is progression free survival (PFS) and adverse events. PFS is defined as the time from the date of randomization to the date of progression or to the date of death, whichever occurs first and disease progression will be evaluated according to RECIST Version 1.1. Adverse events will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0).

Interim analysis

We plan to conduct two interim analyses. The first interim analysis will be conducted independently from the study group when half of the planned number of patients are enrolled and the second interim just after the planned patient accrual is completed. If the superiority of one of test arms is demonstrated with an adjusted α level, the study will be terminated.

In general, the interim reports will contain the following information:

1. Patient accrual rate with a projected completion date (while the study is still accruing)

2. Total patients accrued

3. Distributions of important pretreatment and prognostic baseline variables

4. The frequencies and severity of adverse events by treatment arm.

5. Compliance rates of treatment delivery

6. Observed results with respect to the primary and secondary endpoints

BMJ Open

Ethics and dissemination

This trial has been approved by the Fudan University Shanghai Cancer Center Institutional Review Board (Ethics Committee of Fudan University Shanghai Cancer Center: No.1505146-13). Written informed consent will be obtained from all participants. Serious adverse events will be reported to the safety desk of the trial, the Data and Safety Monitoring Board and trial sites. Trial results will be disseminated via peer reviewed scientific journals and conference presentations.

Participating institutions (From east to west)

Fudan University Shanghai Cancer Center, Huadong Hospital Affiliated to Fudan University, Fudan University Shanghai Cancer Center Minhang Branch, Affiliated Hospital of Jiangnan University, Fujian Province Cancer Hospital, Jiangsu Province Cancer Hospital, The First Affiliated Hospital of Xiamen University, Jiangxi Province Cancer Hospital, Shanxi Province Cancer Hospital, Hainan Province People's Hospital, Gansu Province Cancer Hospital

Trial Status

The trial was initiated in July 2015 and is currently recruiting patients in all of the participating institutions above.

Reference:

- 1. Torre LA, Bray F, Siegel RL, et al. Global Cancer Statistics, 2012. Ca-Cancer J Clin 2015;**65**(2):87-108.
- 2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;**349**(23):2241-52.
- Herskovic A, Martz K, Alsarraf M, et al. Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the Esophagus. New Engl J Med 1992;326(24):1593-98.
- 4. Ajani JA, Ilson DH, Daugherty K, et al. Activity of Taxol in Patients with Squamous-Cell Carcinoma and Adenocarcinoma of the Esophagus. J Natl Cancer I 1994;86(14):1086-91.

BMJ Open

 5. Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008;26(28):4551-56. 6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 2001;24(1):91-95. 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16(9):1090-98. 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of prooperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2001;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(5. Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008;26(28):4551-56. 6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 2001;24(1):91-95. 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16(9):1090-98. 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-	4	
 nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008;26(28):4551-56. 6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 2001;24(1):91-95. 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16(9):1090-98. 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14.	 nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008;26(28):4551-56. 6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 2001;24(1):91-95. 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16(9):1090-98. 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent cisplatin and paclitaxel, advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41. <	3	5. Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two
chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008;26(28):4551-56. 0 6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 11 5-fluorouracil/pacitaxel plus radiotherapy in patients with carcinoma of 12 5-fluorouracil/pacitaxel plus radiotherapy in patients with carcinoma of 13 the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 15 2001;24(1):91-95. 16 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant 18 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 11 trial. Lancet Oncol 2015;16(9):1090-98. 12 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 12 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 12 combined-modality therapy for localized esophageal carcinoma: Initial 13 results. J Thorac Cardiov Sur 2002;124(2):270-77. 14 0. Urba SG, Orringer MB, lanettonni M, et al. Concurrent cisplatin, paclitaxel, and 15 esophageal carcinoma. Cancer 2003;98(10):2177-83. 16 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice	 chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008;26(28):4551-56. 6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 2001;24(1):91-95. 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16(9):1090-98. 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-63. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal carcinoma. Bmc Cancer 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Compl	4	nonoperative regimens of induction chemotherapy followed by
7 Chemoradiation in patients with localized carcinoma of the esophagus: 8 RTOG 0113. J Clin Oncol 2008;26(28):4551-56. 9 6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 11 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of 12 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of 13 the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 14 2001;24(1):91-95. 15 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant 18 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 21 trial. Lancet Oncol 2015;16(9):1090-98. 22 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 23 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent 24 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 25 radiation S, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 26 combined-modality therapy for localized esophageal carcinoma: Initial 27 9. Bains MS, Stojadinovic A, Minsky B, et al. A concurrent cisplatin, paclitaxel, and 28 corbined-mod	r chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008;26(28):4551-56. 10 6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 11 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of 12 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of 13 the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 14 2001;24(1):91-95. 15 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant 16 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 17 7. Shapiro J, Van Lanschot JJB, Holshof MCCM, et al. Neoadjuvant 18 chemoradiatom for esophageal cancer: Cancer Invest 2001;19(1):1-7. 19 piunctional cancer (CROSS): long-term results of a randomised controlled 10 trial. Lancet Oncol 2015;16(9):1090-98. 23 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent 10 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 12 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 10 urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and 11 10. Urba SG, Orringer MB, Ianetto	6	
8 RTOG 0113. J Clin Oncol 2008;26(28):4551-56. 10 6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 11 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of 12 2001;24(1):91-95. 13 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 20 junctional cancer (CROSS): long-term results of a randomised controlled 21 trial. Lancet Oncol 2015;16(9):1090-98. 23 8. Safran H, Gaissert H, Åkerman P, et al. Paclitaxel, cisplatin, and concurrent 24 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 25 combined-modality therapy for localized esophageal carcinoma: Initial 26 combined-modality therapy for localized esophageal carcinoma: Initial 27 radiotherapy as preoperative treatment for patients with locoregional 28 continerapy as preoperative treatment for patients with locoregional 29 advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 20 advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 21 twick cisplatinum and 5-fluorouracil in definitive chemoradiation in 29 advanced esophageal cancer. Ann Oncol 2007;18(1):93	8 RTOG 0113. J Clin Oncol 2008;26(28):4551-56. 10 6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 11 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of 12 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of 13 the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 14 2001;24(1):91-95. 15 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant 18 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 20 junctional cancer (CROSS): long-term results of a randomised concurrent 21 trial. Lancet Oncol 2015;16(9):1090-98. 22 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent 23 R. Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 24 combined-modality therapy for localized esophageal carcinoma: Initial 25 radiotherapy as preoperative treatment for patients with locoregional 26 esophageal carcinoma. Cancer 2003;98(10):2177-83. 21 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, and paclitaxel 26 weekly paclitaxel and cisp	7	chemoradiation in patients with localized carcinoma of the esophagus:
10 6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 11 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of 12 11 13 the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 14 2001;24(1):91-95. 17 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant 18 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 20 junctional cancer (CROSS): long-term results of a randomised controlled 21 trial. Lancet Oncol 2015;16(9):1090-98. 22 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent 24 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 25 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 26 combined-modality therapy for localized esophageal carcinoma: Initial 27 results. J Thorac Cardiov Sur 2002;124(2):270-77. 31 10. Urba SG, Orringer MB, lanettonni M, et al. Concurrent cisplatin, paclitaxel, and 32 radiotherapy as preoperative treatment for patients with locoregional 34 esophageal carcinoma. Cancer 2003;98(10):2177-83.	 6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 2001;24(1):91-95. 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16(9):1090-98. 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagetomy for locally advanced esophageal cancer. Ann Oncol 2001;18(1):93-98. 12. Honing J, Smi JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clin	8	RTOG 0113. J Clin Oncol 2008; 26 (28):4551-56.
11 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of 12 the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 13 2001;24(1):91-95. 16 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant 18 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 11 trial. Lancet Oncol 2015;16(9):1090-98. 12 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 26 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 27 combined-modality therapy for localized esophageal carcinoma: Initial 28 corbined-modality therapy for localized esophageal carcinoma: Initial 29 radiotherapy as preoperative treatment for patients with locoregional 20 esophageal carcinoma. Cancer 2003;98(10):2177-83. 21 10. Urba SG, Orringer MB, lanettonni M, et al. Concurrent cisplatin, paclitaxel, and 28 weekly paclitaxel and cisplatin followed by esophagectomy for locally 29 advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 21 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel 20 with cispla	11 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of 12 the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 13 2001;24(1):91-95. 14 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 11 trial. Lancet Oncol 2015;16(9):1090-98. 12 stafran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent 14 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 15 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 16 combined-modality therapy for localized esophageal carcinoma: Initial 17 results. J Thorac Cardiov Sur 2002;124(2):270-77. 10 Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and 11 Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice 12 weekly paclitaxel and cisplatin followed by esophageatomy for locally 13 advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12 Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel 13 with cisplatinum and 5-fluorouracil in definitive chemoradiation in 12 esop	10	6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent
13 the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 14 2001;24(1):91-95. 17 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant 18 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 11 trial. Lancet Oncol 2015;16(9):1090-98. 12 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent 12 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 12 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 13 combined-modality therapy for localized esophageal carcinoma: Initial 14 results. J Thorac Cardiov Sur 2002;124(2):270-77. 15 10. Urba SG, Orringer MB, lanettonni M, et al. Concurrent cisplatin, paclitaxel, and 18 seophageal carcinoma. Cancer 2003;98(10):2177-83. 19 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice 18 weekly paclitaxel and cisplatin followed by esophagectomy for locally 19 advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12 Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel 14 with cisplatinum and	11 the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 12 2001;24(1):91-95. 13 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant 14 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 15 junctional cancer (CROSS): long-term results of a randomised controlled 16 trial. Lancet Oncol 2015;16(9):1090-98. 17 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent 17 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 17 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 18 combined-modality therapy for localized esophageal carcinoma: Initial 19 results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and 19 radiotherapy as preoperative treatment for patients with locoregional 10 urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and 11 Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice 12 weekly paclitaxel and cisplatin followed by esophagectomy for locally 13 advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 14 12. Honing J, Smit JK	11	5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of
14 2001;24(1):91-95. 15 2001;24(1):91-95. 16 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant 18 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 20 junctional cancer (CROSS): long-term results of a randomised controlled 21 trial. Lancet Oncol 2015;16(9):1090-98. 23 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent 24 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 25 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 26 combined-modality therapy for localized esophageal carcinoma: Initial 27 results. J Thorac Cardiov Sur 2002;124(2):270-77. 31 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and 32 radiotherapy as preoperative treatment for patients with locoregional 34 esophageal carcinoma. Cancer 2003;98(10):2177-83. 35 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice 38 weekly paclitaxel and cisplatin followed by esophagectomy for locally 39 advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.	14 2001;24(1):91-95. 15 2001;24(1):91-95. 16 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant 18 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 11 trial. Lancet Oncol 2015;16(9):1090-98. 22 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent 12 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 23 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 24 combined-modality therapy for localized esophageal carcinoma: Initial 25 results. J Thorac Cardiov Sur 2002;124(2):270-77. 31 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and 26 radiotherapy as preoperative treatment for patients with locoregional 36 esophageal cancerinoma. Cancer 2003;98(10):2177-83. 37 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice 38 weekly paclitaxel and cisplatin followed by esophagectomy for locally 39 advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 41 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and pacl	12	the esonhagus and gastroesonhageal junction. Am I Clin Oncol-Canc
152001;24(1):91-95.167. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant17chemoradiotherapy plus surgery versus surgery alone for oesophageal or18junctional cancer (CROSS): long-term results of a randomised controlled19trial. Lancet Oncol 2015;16(9):1090-98.208. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent21radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7.229. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative23combined-modality therapy for localized esophageal carcinoma: Initial29results. J Thorac Cardiov Sur 2002;124(2):270-77.2110. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and23radiotherapy as preoperative treatment for patients with locoregional24esophageal carcinoma. Cancer 2003;98(10):2177-83.2511. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice28weekly paclitaxel and cisplatin followed by esophagectomy for locally29advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.2112. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel29with cisplatinum and 5-fluorouracil in definitive chemoradiation in29esophageal cancer patients. Ann Oncol 2001;25(3):638-43.20esophageal cancer patients. Ann Oncol 2014;25(3):638-43.2113. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of21definitive chemoradiation in patients with inoperable or irresectable <td>15 2001;24(1):91-95. 16 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant 18 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 21 trial. Lancet Oncol 2015;16(9):1090-98. 22 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent 24 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 25 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 26 combined-modality therapy for localized esophageal carcinoma: Initial 27 9. Bains MS, Stojadinovic A, Minsky B, et al. Concurrent cisplatin, paclitaxel, and 28 combined-modality therapy for localized esophageal carcinoma: Initial 29 results. J Thorac Cardiov Sur 2002;124(2):270-77. 31 10. Urba SG, Orringer MB, lanettonni M, et al. Concurrent cisplatin, paclitaxel, and 32 radiotherapy as preoperative treatment for patients with locoregional 34 esophageal carcinoma. Cancer 2003;98(10):2177-83. 35 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice 36 weekly paclitaxel and cisplatin followed by esophagectomy for locally 36 <t< td=""><td>14</td><td></td></t<></td>	15 2001;24(1):91-95. 16 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant 18 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 21 trial. Lancet Oncol 2015;16(9):1090-98. 22 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent 24 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 25 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 26 combined-modality therapy for localized esophageal carcinoma: Initial 27 9. Bains MS, Stojadinovic A, Minsky B, et al. Concurrent cisplatin, paclitaxel, and 28 combined-modality therapy for localized esophageal carcinoma: Initial 29 results. J Thorac Cardiov Sur 2002;124(2):270-77. 31 10. Urba SG, Orringer MB, lanettonni M, et al. Concurrent cisplatin, paclitaxel, and 32 radiotherapy as preoperative treatment for patients with locoregional 34 esophageal carcinoma. Cancer 2003;98(10):2177-83. 35 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice 36 weekly paclitaxel and cisplatin followed by esophagectomy for locally 36 <t< td=""><td>14</td><td></td></t<>	14	
7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant 18 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 21 trial. Lancet Oncol 2015;16(9):1090-98. 23 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent 24 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 26 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 28 combined-modality therapy for localized esophageal carcinoma: Initial 29 results. J Thorac Cardiov Sur 2002;124(2):270-77. 31 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and 32 radiotherapy as preoperative treatment for patients with locoregional 33 esophageal carcinoma. Cancer 2003;98(10):2177-83. 34 esophageal carcinoma. Cancer 2003;98(10):2177-83. 35 usekly paclitaxel and cisplatin followed by esophagectomy for locally 34 weekly paclitaxel and cisplatin followed by esophagetomy for locally 35 usephageal cancer patients. Ann Oncol 2007;18(1):93-98. 41 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel 42 with ci	107. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant11chemoradiotherapy plus surgery versus surgery alone for oesophageal or12junctional cancer (CROSS): long-term results of a randomised controlled12trial. Lancet Oncol 2015;16(9):1090-98.128. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent12radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7.129. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative12combined-modality therapy for localized esophageal carcinoma: Initial13results. J Thorac Cardiov Sur 2002;124(2):270-77.1410. Urba SG, Orringer MB, lanettonni M, et al. Concurrent cisplatin, paclitaxel, and13radiotherapy as preoperative treatment for patients with locoregional14esophageal carcinoma. Cancer 2003;98(10):2177-83.15Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice16weekly paclitaxel and cisplatin followed by esophagectomy for locally17advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.18L2. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel19with cisplatinum and 5-fluorouracil in definitive chemoradiation in19esophageal cancer patients. Ann Oncol 2014;25(3):638-43.1613. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of17definitive chemoradiation in patients with inoperable or irresectable18esophageal carcinoma. Bmc Cancer 2014;14.1914. Lakatos E. Designing complex group sequen	15	2001;24(1):91-95.
18 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 12 trial. Lancet Oncol 2015;16(9):1090-98. 13 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent 14 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 16 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 17 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 18 combined-modality therapy for localized esophageal carcinoma: Initial 19 results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and 18 esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice 18 weekly paclitaxel and cisplatin followed by esophagectomy for locally 19 advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 11. Lin CC, Hsu CH, Kuujis CT, et al. A comparison of carboplatin and paclitaxel 19 with cisplatinum and 5-fluorouracil in definitive chemoradiation in 12 Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel 13	18 chemoradiotherapy plus surgery versus surgery alone for oesophageal or 19 junctional cancer (CROSS): long-term results of a randomised controlled 21 trial. Lancet Oncol 2015;16(9):1090-98. 22 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent 24 radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 25 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 26 combined-modality therapy for localized esophageal carcinoma: Initial 27 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative 28 combined-modality therapy for localized esophageal carcinoma: Initial 29 radiotherapy as preoperative treatment for patients with locoregional 30 radiotherapy as preoperative treatment for patients with locoregional 31 esophageal carcinoma. Cancer 2003;98(10):2177-83. 32 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice 33 weekly paclitaxel and cisplatin followed by esophagectomy for locally 34 weekly paclitaxel and cisplatin followed by esophagetary with twice 35 usphageal cancer patients. Ann Oncol 2007;18(1):93-98. 36 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitax	18	7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant
 junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16(9):1090-98. 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 	 junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16(9):1090-98. 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41. 	18	chemoradiotherapy plus surgery versus surgery alone for oesophageal or
111trial. Lancet Oncol 2015; 16(9):1090-98.28. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent2radiation for esophageal cancer. Cancer Invest 2001; 19(1):1-7.29. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative28combined-modality therapy for localized esophageal carcinoma: Initial29results. J Thorac Cardiov Sur 2002; 124(2):270-77.3110. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and33radiotherapy as preoperative treatment for patients with locoregional34esophageal carcinoma. Cancer 2003; 98(10):2177-83.3511. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice38weekly paclitaxel and cisplatin followed by esophagectomy for locally39advanced esophageal cancer. Ann Oncol 2007; 18(1):93-98.4112. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel43with cisplatinum and 5-fluorouracil in definitive chemoradiation in44esophageal cancer patients. Ann Oncol 2014; 25(3):638-43.4513. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of46definitive chemoradiation in patients with inoperable or irresectable4714. Lakatos E. Designing complex group sequential survival trials. Stat Med482002; 21(14):1969-89.	20121trial. Lancet Oncol 2015;16(9):1090-98.228. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent23radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7.249. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative25combined-modality therapy for localized esophageal carcinoma: Initial26results. J Thorac Cardiov Sur 2002;124(2):270-77.3110. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and33radiotherapy as preoperative treatment for patients with locoregional34esophageal carcinoma. Cancer 2003;98(10):2177-83.3511. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice38weekly paclitaxel and cisplatin followed by esophagectomy for locally39advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.4112. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel43with cisplatinum and 5-fluorouracil in definitive chemoradiation in44esophageal cancer patients. Ann Oncol 2014;25(3):638-43.4513. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of46definitive chemoradiation in patients with inoperable or irresectable47esophageal carcinoma. Bmc Cancer 2014;14.482002;21(14):1969-89.49courcinoma. Bmc Cancer 2014;14.41Lakatos E. Designing complex group sequential survival trials. Stat Med422002;21(14):1969-89.4315. Lakatos E. Sample Sizes Based on the Log-	19 20	junctional cancer (CROSS): long-term results of a randomised controlled
 B. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. B. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77. U. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. Loning J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 	 Bindle Concol 2015;16(9):1090-96. B. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. P. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophageatcomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41. 	20	
 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 	 8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7. 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41. 	22	trial. Lancet Uncol 2015; 16 (9):1090-98.
24radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7.269. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative27combined-modality therapy for localized esophageal carcinoma: Initial28combined-modality therapy for localized esophageal carcinoma: Initial29results. J Thorac Cardiov Sur 2002;124(2):270-77.3110. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and33radiotherapy as preoperative treatment for patients with locoregional34esophageal carcinoma. Cancer 2003;98(10):2177-83.3511. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice38weekly paclitaxel and cisplatin followed by esophagectomy for locally39advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.4112. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel43with cisplatinum and 5-fluorouracil in definitive chemoradiation in44esophageal cancer patients. Ann Oncol 2014;25(3):638-43.4513. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of48definitive chemoradiation in patients with inoperable or irresectable49esophageal carcinoma. Bmc Cancer 2014;14.5114. Lakatos E. Designing complex group sequential survival trials. Stat Med532002;21(14):1969-89.	22radiation for esophageal cancer. Cancer Invest 2001;19(1):1-7.239. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative24combined-modality therapy for localized esophageal carcinoma: Initial25results. J Thorac Cardiov Sur 2002;124(2):270-77.2610. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and27radiotherapy as preoperative treatment for patients with locoregional28esophageal carcinoma. Cancer 2003;98(10):2177-83.2911. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice29weekly paclitaxel and cisplatin followed by esophagectomy for locally29advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.2112. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel24with cisplatinum and 5-fluorouracil in definitive chemoradiation in24esophageal cancer patients. Ann Oncol 2014;25(3):638-43.2513. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of26definitive chemoradiation in patients with inoperable or irresectable27esophageal carcinoma. Bmc Cancer 2014;14.282002;21(14):1969-89.2915. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex201Clinical-Trials. Biometrics 1988;44(1):229-41.	23	8. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent
 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 	26 279. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77.31 3210. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83.36 37 36 3711. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.41 42 43 44 44 45 46 4112. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43.44 45 46 47 48 4713. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14.49 40 412002;21(14):1969-89.41 45 4615. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89.45 45 45 4515. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41.	25	radiation for esophageal cancer. Cancer Invest 2001; 19 (1):1-7.
272728combined-modality therapy for localized esophageal carcinoma: Initial28combined-modality therapy for localized esophageal carcinoma: Initial30results. J Thorac Cardiov Sur 2002;124(2):270-77.3110. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and33radiotherapy as preoperative treatment for patients with locoregional34esophageal carcinoma. Cancer 2003;98(10):2177-83.3511. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice38weekly paclitaxel and cisplatin followed by esophagectomy for locally39advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.4112. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel43with cisplatinum and 5-fluorouracil in definitive chemoradiation in44esophageal cancer patients. Ann Oncol 2014;25(3):638-43.4513. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of48definitive chemoradiation in patients with inoperable or irresectable49esophageal carcinoma. Bmc Cancer 2014;14.5114. Lakatos E. Designing complex group sequential survival trials. Stat Med532002;21(14):1969-89.	2728combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002; 124 (2):270-77.3110. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003; 98 (10):2177-83.3611. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007; 18 (1):93-98.4112. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014; 25 (3):638-43.4313. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014; 14 .442002; 21 (14):1969-89.4515. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002; 21 (14):1969-89.4615. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988; 44 (1):229-41.	26	9. Bains MS. Stojadinovic A. Minsky B. et al. A phase II trial of preoperative
 results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 	 combined-modality therapy for tocalized esophagear carcinolita: initial results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41. 	27	combined modelity thereasy for legalized econhogoal enginema. Initial
30results. J Thorac Cardiov Sur 2002;124(2):270-77.3110. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and33radiotherapy as preoperative treatment for patients with locoregional34esophageal carcinoma. Cancer 2003;98(10):2177-83.3511. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice38weekly paclitaxel and cisplatin followed by esophagectomy for locally39advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.4112. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel43with cisplatinum and 5-fluorouracil in definitive chemoradiation in44esophageal cancer patients. Ann Oncol 2014;25(3):638-43.4613. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of48definitive chemoradiation in patients with inoperable or irresectable49esophageal carcinoma. Bmc Cancer 2014;14.5114. Lakatos E. Designing complex group sequential survival trials. Stat Med532002;21(14):1969-89.	30results. J Thorac Cardiov Sur 2002;124(2):270-77.3110. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83.3611. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.4112. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43.4613. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14.5114. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89.5415. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41.	29	combined-modanty therapy for localized esophageal carcinoma: initial
31 3210. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83.36 3711. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.41 42 4312. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43.46 47 48 48 49 49 49 4013. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14.51 51 5314. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89.	31 3210. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83.36 3711. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.41 42 43 4412. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43.46 47 48 49 49 49 4013. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14.51 52 53 54 55 54 55 54 55 55 56 56 56 56 56 56 56 56 56 56 56 56 56 56 56 57 57 58	30	results. J Thorac Cardiov Sur 2002; 124 (2):270-77.
33radiotherapy as preoperative treatment for patients with locoregional34esophageal carcinoma. Cancer 2003;98(10):2177-83.3611. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice38weekly paclitaxel and cisplatin followed by esophagectomy for locally39advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.4112. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel43with cisplatinum and 5-fluorouracil in definitive chemoradiation in45esophageal cancer patients. Ann Oncol 2014;25(3):638-43.4613. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of47definitive chemoradiation in patients with inoperable or irresectable49esophageal carcinoma. Bmc Cancer 2014;14.5114. Lakatos E. Designing complex group sequential survival trials. Stat Med532002;21(14):1969-89.	33radiotherapy as preoperative treatment for patients with locoregional34esophageal carcinoma. Cancer 2003;98(10):2177-83.3511. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice37weekly paclitaxel and cisplatin followed by esophagectomy for locally39advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.4112. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel43with cisplatinum and 5-fluorouracil in definitive chemoradiation in45esophageal cancer patients. Ann Oncol 2014;25(3):638-43.4613. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of47definitive chemoradiation in patients with inoperable or irresectable49esophageal carcinoma. Bmc Cancer 2014;14.5114. Lakatos E. Designing complex group sequential survival trials. Stat Med532002;21(14):1969-89.5415. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex55Clinical-Trials. Biometrics 1988;44(1):229-41.	31	10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and
 esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 	 esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41. 	33	radiotherapy as preoperative treatment for patients with locoregional
 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 	 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41. 	34	esonhageal carcinoma Cancer 2003: 98 (10):2177-83
 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 	 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41. 	35 36	44 Li CO IL CIL LO LA LO LA
 weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 	 weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41. 	37	11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice
39 40advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.4112. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel42with cisplatinum and 5-fluorouracil in definitive chemoradiation in44esophageal cancer patients. Ann Oncol 2014;25(3):638-43.4613. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of47definitive chemoradiation in patients with inoperable or irresectable49esophageal carcinoma. Bmc Cancer 2014;14.5114. Lakatos E. Designing complex group sequential survival trials. Stat Med532002;21(14):1969-89.	39 40advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.41 4212. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel43 44 45with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43.46 47 48 46 4713. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14.51 52 53 54 5514. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89.54 55 56 56 5715. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41.	38	weekly paclitaxel and cisplatin followed by esophagectomy for locally
 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 	 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41. 	39 40	advanced esophageal cancer. Ann Oncol 2007; 18 (1):93-98.
 42 43 44 45 46 47 48 47 48 46 49 50 47 48 46 47 48 47 48 49 49 49 41 42 44 45 44 45 44 45 45 46 47 47 48 49 49 40 41 42 44 45 44 45 45 46 47 47 48 49 49 49 40 41 42 44 45 44 45 44 45 45 46 47 47 48 49 49 49 40 40 41 42 44 45 44 45 45 46 47 47 48 49 49 49 40 40 41 41 42 42 44 44 45 44 45 45 46 47 47 48 49 49 49 40 40 41 41 42 43 44 44 45 44 45 45 46 47 47 48 49 49 49 40 40 41 41 42 44 44 45 44 45 45 46 47 48 <	 42 with cisplatinum and 5-fluorouracil in definitive chemoradiation in 43 esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 46 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of 48 definitive chemoradiation in patients with inoperable or irresectable 49 esophageal carcinoma. Bmc Cancer 2014;14. 51 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 53 2002;21(14):1969-89. 54 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex 56 Clinical-Trials. Biometrics 1988;44(1):229-41. 	41	12 Honing I Smit IK Muiis CT et al. A comparison of carbonlatin and paclitaxel
 with displatinum and 5-fluorouracii in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 	 with displatinum and 5-fluorouracii in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41. 	42	
 esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 	 esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41. 	43 44	with displatinum and 5-fluorouracil in definitive chemoradiation in
 46 47 48 49 50 50 51 52 53 2002;21(14):1969-89. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 	 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;21(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41. 	45	esophageal cancer patients. Ann Oncol 2014; 25 (3):638-43.
4748definitive chemoradiation in patients with inoperable or irresectable48esophageal carcinoma. Bmc Cancer 2014;14.5014. Lakatos E. Designing complex group sequential survival trials. Stat Med522002;21(14):1969-89.	47definitive chemoradiation in patients with inoperable or irresectable48definitive chemoradiation in patients with inoperable or irresectable49esophageal carcinoma. Bmc Cancer 2014;14.5014. Lakatos E. Designing complex group sequential survival trials. Stat Med522002;21(14):1969-89.5415. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex56Clinical-Trials. Biometrics 1988;44(1):229-41.58	46	13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of
 49 50 50 51 51 52 53 2002;21(14):1969-89. 	 49 esophageal carcinoma. Bmc Cancer 2014;14. 51 52 53 54 55 54 55 55 56 56 57 58 	47 48	definitive chemoradiation in patients with inoperable or irresectable
505114. Lakatos E. Designing complex group sequential survival trials. Stat Med522002; 21 (14):1969-89.	 state of the set of the	49	aconhagoal garginoma. Pmg Canger 2014.14
5114. Lakatos E. Designing complex group sequential survival trials. Stat Med522002; 21 (14):1969-89.	5114. Lakatos E. Designing complex group sequential survival trials. Stat Med522002; 21 (14):1969-89.5415. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex56Clinical-Trials. Biometrics 1988; 44 (1):229-41.5758	50	esophageal carcinoma. Bmc Cancer 2014; 14 .
⁵² 2002; 21 (14):1969-89.	53 2002;21(14):1969-89. 54 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex 55 Clinical-Trials. Biometrics 1988;44(1):229-41. 57 58	51	14. Lakatos E. Designing complex group sequential survival trials. Stat Med
	 54 55 56 57 58 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex 56 Clinical-Trials. Biometrics 1988;44(1):229-41. 	53	2002; 21 (14):1969-89.
54 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex	56 Clinical-Trials. Biometrics 1988; 44 (1):229-41. 58	54	15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex
56 Clinical Triala Diametrica 1090.44(1):220.41	57 58	55 56	(linical Trials Diametrics 1000, $AA(1)$, 220, 41
57 Children - Trials, Biometrics 1988; 44 (1):229-41.	58	57	Chinical-Thais. Biometrics 1966; $44(1)$: 229-41.
58 1·	1	58	14
	60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	עכ 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
12	
10	
20	
20	
21	
22	
∠3 ⊃4	
24	
25	
26	
2/	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
52	
59	
50	

1

Declarations	
List of abbreviations	
TP: Paclitaxel combined with cisplatin	
TC: Paclitaxel combined with carboplatin	
TF: Paclitaxel combined with fluorouracil	
UICC: Union for International Cancer Control	
ESCC: Esophageal squamous cell carcinoma	
PF: Cisplatin combined with fluorouracil	
AIDS: Acquired immune deficiency syndrome	
RT: Radiotherapy	
PTX: Paclitaxel	
DDP: Cisplatin	
CBP: Carboplatin	
5-FU: Fluorouracil	
W: Week	
ICRU: International Commission on Radiation Units and Measurements	
GTV: Gross Target Volume	
CTV: Clinical Target Volume	
PTV: Planning Target Volume	
WBC: White Blood Cell	
ANC: Absolute Neutrophil Counts	
Hb: Hemoglobin	
Plt: Platelet	
ULN: Upper Limit of Normal	
AST: Aspartate Transaminase	
ALT: Alanine aminotransferase	
Consent of publication	
Not applicable	
Declaration of interests	

We declare no competing interests.

15

BMJ Open

Funding

The study was supported by 2015 Prospective Clinical Research Fund of Fudan University Shanghai Cancer Center.

Author's contributions

D Ai was responsible for drafting the manuscript. Y Chen, Q Liu, J Zhang, J Deng, H Zhu, W Ren, K Wu, M Fan, H Yang, Z Zhu, W Zhao, L Li were responsible for the collection of previous study and putting forward the conception. X Zheng, Y Li, J Ye, J Zhou, Q Lin, H Luo, J Cao, S Wei, J Fan, J Li, G Huang and H Badakhshi were responsible for designing the details of the study. K Zhao was responsible for all aspects of trial design, the protocol and trial conduct. All authors have read and approved this manuscript.



Fig1. Treatment design of the ESO-Shanghai 2 trial. RT=radiotherapy, PTX=paclitaxel, DDP=cisplatin, 5-Fu=fluorouracil, CBP=carboplatin, W=Week.

BMJ Open

BMJ Open

Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2)

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-020785.R1
Article Type:	Protocol
Date Submitted by the Author:	17-Mar-2018
Complete List of Authors:	 Ai, Dashan; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Chen, Yun; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Liu, Qi; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhang, Junhua; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Deng, Jiaying; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Deng, Jiaying; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhu, Hanting; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Ren, Wenjia; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhu, Hanting; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Radiation Oncology Li, Yunhai; Fudan University Shanghai Cancer Center Minhang Branch Hospital, Department of Radiation Oncology Wei, Shihong; Gansu Province Cancer Hospital, Department of Radiation Oncology Yee, Jinjun; Jiangsu Cancer Hospital, Department of Radiation Oncology Lin, Qin; First Affiliated Hospital of Xiamen University, Department of Radiation Oncology Luo, Hui; Jiangxi Province Cancer Hospital, Department of Radiation Oncology Luo, Hui; Jiangxi Province Cancer Hospital, Department of Radiation Oncology<

	Oncology Huang, Guang; Hainan Province People's Hospital, Department of Radiation Oncology Wu, Kailiang; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Fan, Min; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Yang, Huanjun; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhu, Zhengfei; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhu, Zhengfei; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhao, Weixin; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Li, Ling; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Li, Ling; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Fan, Jianhong; Renhe Hospital, Department of Gynecology Badakhshi, Harun; Charite´ School of Medicine and Centre for Cancer Medicine, Department of Radiation Oncology Zhao, Kuaile; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology
Primary Subject Heading :	Oncology
Secondary Subject Heading:	Oncology
Keywords:	esophageal squamous cell carcinoma, concurrent chemoradiotherapy, paclitaxel, cisplatin, carboplatin, fluorouracil
	SCHOLARONE [™] Manuscripts



BMJ Open

Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2) Dashan Ai^{1, 2}, Yun Chen^{1, 2}, Qi Liu^{1, 2}, Junhua Zhang^{1, 2}, Jiaying Deng^{1, 2}, Hanting Zhu^{1, 2}, Wenjia Ren^{1, 2}, Xiangpeng Zheng³, Yunhai Li⁴, Shihong Wei⁵, Jinjun Ye⁶, Jialiang Zhou⁷, Qin Lin⁸, Hui Luo⁹, Jianzhong Cao¹⁰, Jiancheng Li¹¹, Guang Huang¹², Kailiang Wu^{1, 2}, Min Fan^{1, 2}, Huaniun Yang^{1, 2}, Zhengfei Zhu^{1, 2}, Weixin Zhao^{1, 2}, Ling Li^{1, 2}, Jianhong Fan¹³, Harun Badakhshi¹⁴, Kuaile Zhao^{1, 2} 1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China 3. Department of Radiation Oncology, Huadong Hospital Affiliated to Fudan University, Shanghai, China 4. Department of Radiation Oncology, Fudan University Shanghai Cancer Center Minhang Branch Hospital, Shanghai, China 5. Department of Radiation Oncology, Gansu Province Cancer Hospital, Lanzhou, China 6. Department of Radiation Oncology, Jiangsu Province Cancer Hospital, Nanjing, China 7. Department of Radiation Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China 8. Department of Radiation Oncology, First Affiliated Hospital of Xiamen University, Xiamen, China 9. Department of Radiation Oncology, Jiangxi Province Cancer Hospital, Nanchang, China 10. Department of Radiation Oncology, Shanxi Province Cancer Hospital, Taiyuan, China 11. Department of Thoracic Radiation Oncology, Fujian Province Cancer Hospital, Fuzhou, China 12. Department of Radiation Oncology, Hainan Province People's Hospital, Haikou, China

60

BMJ Open

1	
2	
5 4	13. Department of Gynecology, Renhe hospital, Shanghai, China
5	14. Department of Radiation Oncology, Charite' School of Medicine and Centre for
6 7	Cancer Medicine, Berlin, Germany
8	Corresponding author: Kuaile Zhao 270 Dongan Rd Shanghai 200032 China Email
9	
10	<u>kuaile_z(a)shca.org.cn</u> . 1el: +86-21-641/5590
11 12	Key words: esophageal squamous cell carcinoma, concurrent chemoradiotherapy,
13	paclitaxel, cisplatin, carboplatin, fluorouracil
14	
15	Word counts: 2,856 words
16	
/ 19	
10	
20	
21	
22	
23	
24	
25	
26 27	
27	
29	
30	
31	
32	
33	
34	
30 36	
37	
38	
39	
40	
41	
42	
чэ 44	
45	
46	
47	
48	
49	
50	
51 52	
53	
54	
55	
56	
57	
58	2

Abstract

Introduction: Concurrent chemoradiation is the standard therapy for patients with local advanced esophageal carcinoma unsuitable for surgery. Paclitaxel is an active agent against esophageal cancer and it has been proved as a potent radiation sensitizer. There have been multiple studies evaluating paclitaxel-based chemoradiation in esophageal cancer, the results of which are inspiring. However, which regimen. among paclitaxel in combination with cisplatin (TP), carboplatin (TC) and fluorouracil (TF) concurrent with radiotherapy, provides best prognosis with minimum adverse events is still considered far from resolved and very few studies focus on this field. The purpose of this study is to confirm the priority of TF to TP or TC concurrent with radiotherapy in terms of overall survival and propose a feasible and effective plan for patients with local advanced esophageal cancer. Methods and analysis: ESO-Shanghai 2 is a three-arm, multicenter, open-labeled, randomized phase III clinical trial. The study was initiated in July 2015 and the duration of inclusion will be 4 years. The study compares two pairs of regimen: TF versus TP and TF versus TC concurrent with definitive radiotherapy for patients with esophageal squamous cell carcinoma (ESCC). Patients with histologically confirmed ESCC (clinical stage II, III or IVa based on the 6th UICC-TNM classification) and without any prior treatment of chemotherapy, radiotherapy or surgery against esophageal cancer will be eligible. A total of 321 patients will be randomized and allocated in a 1:1:1 ratio to the three treatment groups. Patients are stratified by lymph node status (N0, N1, M1a). The primary endpoint is overall survival and the secondary endpoint is progression-free survival and adverse events. Ethics and dissemination:

This trial has been approved by the Fudan University Shanghai Cancer Center Institutional Review Board. Trial results will be disseminated via peer reviewed scientific journals and conference presentations.

Trial registration: Clinicaltrials.gov: NCT02459457

1	
2	
3 A	Strengths and limitations of this study
5	• First phase III randomized multi-centered study comparing these three regimens
6 7	• Stratification by lymph node status (N0, N1, M1a based on the 6 th UICC-TNM
8	classification)
9	 No stratification for different centers
10 11	• No stratification for different centers
12	
13	
14	
16	
17	
18	
19 20	
20	
22	
23	
24 25	
26	
27	
28	
29 30	
31	
32	
33	
35	
36	
37	
38 39	
40	
41	
42	
43	
45	
46	
47 48	
49	
50	
51	
52 53	
54	
55	
56 57	
58	
59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Introduction

Worldwide, esophageal cancer is the eighth most common cancer, which is responsible for an estimated 455,800 new cases and 400,200 deaths in 2012.¹ Since its prognosis is dismal, much effort has been put into improving overall survival through multi-modality treatments, which consist of surgery, radiotherapy and chemotherapy.² Concurrent chemoradiation is the standard non-operative therapy for local advanced esophageal squamous cell carcinoma (ESCC).³

Paclitaxel is an active agent against esophageal cancer, with the response rate of 28% in ESCC, and it has been shown to be a potent radiation sensitizer.⁴ There have been multiple studies evaluating paclitaxel-based chemoradiation in esophageal cancer, for instance, paclitaxel/fluorouracil (TF) developed at The University of Texas M.D. Anderson Cancer Center, and paclitaxel/cisplatin (TP) developed at Memorial Sloan-Kettering Cancer Center, ⁵⁶ with paclitaxel/carboplatin (TC) from CROSS trial.⁷ In many preoperative studies, paclitaxel-based chemoradiotherapy has achieved inspiring effect, the pathologic complete response rates of TP-based chemoradiotherapy were 19%-42%, ⁸⁻¹¹ and of TC-based chemoradiotherapy was 49%.⁷ However, which regimen, among TF, TP and TC-based definitive chemoradiotherapy, provides best prognosis with minimum adverse events is still considered far from resolved and very few studies focus on this field.

RTOG 0113⁵ evaluated 2 different paclitaxel-based regimens (TP and TF). Eighty-four patients were accrued to this study. Patients in arm A (TF) received induction 5-FU, cisplatin, and paclitaxel followed by radiation and concurrent continuous infusion 5-FU and weekly paclitaxel. Patients in arm B (TP) received induction paclitaxel and cisplatin followed by radiation and concurrent weekly cisplatin and 96-hour infusion of paclitaxel. The median survival time was 28.7 months for patients in arm A (TF) and 14.9 months for patients in arm B (TP). Neither arm achieved the hypothesized 1-year survival rate of at least 77.5%. The main deficiency of this study is the small sample size, but the effect of TF group is still inspiring.

Another retrospective multicenter randomize clinical trials from Europe¹² showed the overall survival of TC-based definitive chemoradiotherapy was comparable with cisplatin/5-FU (PF) as definitive concurrent chemoradiotherapy in

BMJ Open

esophageal cancer. However, the toxicity rates were lower in the TC group together with higher treatment compliance.

Based on RTOG 0113 and other reports, we designed a multicenter randomized controlled phase III trial to confirm the priority of TF to TP and TF to TC concurrent with radiotherapy in terms of overall survival for patients with local advanced esophageal squamous cell carcinoma. Independent ethics committees of the participating centers approved the study protocol. This trial has been registered with ClinicalTrials.gov, number NCT02459457.

The trial is a three-arm, multicenter, open-labeled, randomized phase III clinical trial. The study was initiated in July 2015 and the duration of inclusion will be 4 years. The study compares two pairs of regimen: TF versus TP and TF versus TC concurrent with definitive radiotherapy in patients with esophageal squamous cell carcinoma.

Methods and analysis

Patient selection

To be eligible for this study, patient must fulfill all of the following criteria (Table 1):

Inclusion criteria

- 1. Histologically confirmed esophageal squamous cell carcinoma
- 2. Clinical stages II, III or IVa based on the 6th UICC-TNM classification
- 3. No prior treatment of chemotherapy, radiotherapy or surgery against esophageal cancer, except for non-curative resection by EMR/ESD.
- 4. Aged 18-75 years
- 5. Adequate organ functions for chemoradiation therapy
 - a) White blood cell (WBC) $\geq 3 \times 10^{9}$ /L
 - b) Absolute neutrophil counts (ANC) $\geq 1.5 \times 10^{9}/L$
 - c) Hemoglobin (Hb) $\geq 10g/dl$
 - d) Platelet (Plt) $\geq 100 \times 10^{9}$ /L
 - e) Total bilirubin <1.5 upper limit of normal (ULN)
 - f) Aspartate transaminase (AST) ≤ 2.5 ULN
 - g) Alanine aminotransferase (ALT) ≤ 2.5 ULN

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
11	
12	
13	
14	
15	
16	
17	
18	
10	
20	
20	
21	
22	
23	
24	
25	
26	
27	
22	
20	
29	
30	
31	
32	
33	
34	
35	
36	
27	
27	
38	
39	
40	
41	
42	
43	
44	
45	
16	
40	
4/	
48	
49	
50	
51	
52	
53	
54	
54	
22	
20	
5/	
58	
59	

1

h) Creatinine ≤1.5 ULN

6. ECOG PS of 0-2

7. Life expectancy \geq 3 months

8. Written informed consent

Table 1. Inclusion criteria

Patients fulfilling any of the following criteria are ineligible for this study (Table 2).

Exclusion criteria

1. Esophageal perforation or hematemesis

2. Synchronous or metachronous malignancies (except for cutaneous (non-melanomas) carcinoma, thyroid papillary carcinoma, phase I seminoma or cervical carcinoma in situ curatively treated and disease free for a minimum of 3 months)

3. Received thoracic, abdominal or craniocerebral surgery within 30 days

4. Enrolled in other clinical trials within 30 days

5. Unstable angina and/or congestive heart failure requiring hospitalization within 6 months

6. Severe psychiatric disease

7. Pregnancy, lactation or unwillingness to adopt contraception

8. Drug addiction

9. Acquired immune deficiency syndrome (AIDS) based upon current CDC definition

10. History of radiotherapy in the planning area

11. Other ineligible conditions according to researchers

Table 2. Exclusion criteria

Treatment

The treatment plan is shown in Figure 1. Patients receive radiotherapy combined with concurrent chemotherapy. Radiotherapy begins on day 1, concurrent with the beginning of cycle 1 of chemotherapy.

Same radiation therapy will be delivered in all three treatment groups. Radiotherapy is delivered with photons (≥ 6 MV) to a total dose of 61.2Gy in 34 fractions. Patients will be treated 5 days per week at 1.8Gy/d. Three-dimensional

BMJ Open

conformal radiotherapy or intensity modulated radiotherapy is required. All patient will be positioned in an individualized immobilization device in the treatment position.

The definition of volumes will be in accordance with the 1993 ICRU Report #50 and 1999 ICRU Report #62.

The gross target volume (GTV) is defined as all known involved field, which detected by endoscopic ultrasound, barium swallow or CT scan (whichever is larger). The regional lymph nodes included in GTV is whose diameter more than 1cm (0.5cm for lymph nodes at tracheoesophageal groove) or histologically proven metastatic after puncture.

The superior and inferior borders of the clinical target volume (CTV) are 3cm beyond the primary tumor along the esophagus. The lateral, anterior and posterior borders of the field are the same as GTV.

The superior, inferior, anterior, posterior and lateral borders of planning target volume (PTV) are 1cm beyond CTV. Field next to the spinal cord could be slightly adjusted in order to reduce the exposure of spinal cord.

As for target volume, tissue inhomogeneity correction is adopted and it is required that more than 99% PTV receive 95% prescription dose and more than 95% PTV receive 99% or more prescription dose. Highest and lowest point dose inside PTV should be recorded.

When making the treatment plan, we should take normal organ dose restrictions into consideration as the following order: (Table 3)

Risk organ	Contour regulation	Dose restriction
Spinal cord	All the layers of CT scan have	Highest point dose less
	to be contoured and the margin	than 45Gy
	of vertebra tube can be	
	regarded as that of planning	
	organ at risk volume.	
Lung	It is allowed to use automatic	The volume of lung (PTV
	tools in the delineation of	excluded) receiving 20Gy
	margin of lungs. (Trachea and	or higher has to be less

1	
2	
3	
4	
5	
6	
7	
, 0	
0	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
20 21	
∠ I 22	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
37	
22	
ככ ⊃∡	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
77 15	
45	
40	
4/	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
50	
20	
59	

	bronchia must be contoured	than 30% of the total lung
	manually)	volume, and the mean
		dose has to be less than
		15Gy.
Heart	The superior margin of heart	The mean dose has to be
	consists of right atrium and	less than 40Gy.
	right ventricle, pulmonary	
	artery trunk, ascending main	
	aorta and superior vena cava	
	excluded. The inferior margin	
	is at the level of heart apex.	
	<u> </u>	

Table 3. Contour regulation and dose restriction of risk organs

Chemotherapy

Patients are randomly assigned to receive one of three therapies.

Arm A (TP)

Patients in arm A receive 4 courses of TP every 4 weeks. Details are as follows:

Paclitaxel: 175mg/m²/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m²/d, ivgtt, d1-3;

Arm B (TF)

Patients in arm B receive 6 courses of TF concurrent with radiotherapy every week and 2 courses of TF consolidation chemotherapy every 4 weeks. Details are as follows:

Concurrent: paclitaxel 50mg/m²/d, ivgtt over 3 hours, d1; 5-FU 300mg/m², civ 96h, d1-4

Consolidation: paclitaxel 175 mg/m²/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m², civ 72h, d1-3

Arm C (TC)

Patients in arm C receive 6 courses of TC concurrent with radiotherapy every week and 2 courses of TC consolidation chemotherapy every 4 weeks. Details are as follows:

Concurrent: paclitaxel 50mg/m²/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1

Consolidation: paclitaxel 175 mg/m²/d, ivgtt over 3 hours, d1; carboplatin AUC=5,

1	
2 3	ivgtt, dl
4 5	Patients receive premedication to prevent allergic reaction and significant nausea or
6	vomiting as indicated
7 8	volinting us indicated.
9	
10 11	Dose modifications
12	Radiotherapy interruption
13	If following toxicity is observed, radiotherapy has to be delayed until toxicity is no
14	more than grade 2.
16 17	• WBC< 2.0×10^{9} /L or ANC< 1.0×10^{9} /L
17	• $Plt < 50 \times 10^9/L$
19 20	• Grade 3 or higher non-hematological toxicity
21	If following toxicity is observed, radiotherapy has to be delayed until complete
22 23	recovery.
24 25	• Mediastinal or thoracic infection with fever over 38.5
25 26	It is allowed to suspend at most 2 weeks, or radiotherapy will be terminated
27	It is anowed to suspend at most 2 weeks, of radiotherapy will be terminated.
28 29	
30	Chemotherapy interruption and dose modifications
31 32	If following toxicity is observed on day 1, chemotherapy has to be delayed until
33	toxicity is no more than grade 1.
34 35	• ANC< 1.5×10^{9} /L
36	• $Plt < 100 \times 10^9/L$
37 38	• Grade 2 or higher non-hematological toxicity except for nauseal vomiting and
39	alonecia
40 41	
42	It is allowed to delay at most 2 weeks, or chemotherapy will be terminated.
43	Chemotherapy dose modifications are based on the greatest toxicity during the last
44	cycle. Any patients who need to make chemotherapy dose modifications will receive
46	the modified dose in the following cycles.
47 48	If modifications are needed, dose of paclitaxel, cisplatin, carboplatin and 5-FU will
49 50	decreased by 25% from the planned dose for the first time and 50% for the second
51	time. It is allowed to make dose modifications at most twice, or chemotherapy will be
52 53	terminated. Details are as follows:
54 55	Dose modification of paclitaxel
56	• Febrile neutropenia (ANC< 0.5×10^9 /L and fever over $38.3 \square$ or over $38.0 \square$ for
57 58	
59	10
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1h)

• Grade 2 or higher peripheral neuropathy

Dose modification of cisplatin and carboplatin

• Febrile neutropenia (ANC< 0.5×10^{9} /L and fever over 38.3 or over 38.0 for

1h)

- Grade 2 or higher peripheral neuropathy
- Serum creatinine >3ULN

Dose modification of 5-FU

• Febrile neutropenia (ANC< 0.5×10^9 /L and fever over $38.3 \square$ or over $38.0 \square$ for 1h)

• Grade 3 or higher mucositis

The adverse events will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0). All adverse events, occurring during the course of the trial, which is from randomization until 28 days after end of treatment, regardless of relatedness to study medication, will be recorded. Adverse events occurring later than 28 days after the end of treatment will only be recorded if they are considered relevant.

Randomization

After the confirmation of eligibility criteria, patients will be randomly allocated in a 1:1:1 ratio to the three treatment groups by a central randomization center (Fudan University Shanghai Cancer Center, Shanghai, China). Patients will be stratified by lymph node status (N0, N1, M1a). The SAS was used to generate a random permutation sequence and produce patient randomization numbers. The data center registers the enrollment, assigns a unique identification number to every participant, and replies to the respective investigators.

Sample size calculation and statistical analysis

This three-arm randomized trial is designed to confirm whether TF is superior to TP or TC concurrent with radiotherapy in terms of overall survival. According to RTOG

BMJ Open

0113 and other reports, median survival time of TF concurrent with radiotherapy for esophageal cancer is 28.7 months while TP 14.9 months⁵ and TC 17.4 months¹³. According to the Schoenfeld and Richter's method, the sample size of 107 patients per arm (154 events in total) is required to warrant a power of 80% at a two-sided α level of 0.025 for the comparison between TP and TF with relatively smaller difference, assuming an accrual period of 48 months, a minimum follow-up period of 24 months and a dropout rate of 10%^{14 15}. The total sample size is planned as 321 patients (107 patients in each arm, a total of 231 events).

The median overall survival will be estimated with Kaplan-Meier method, and log-rank test will be used to compare the overall survival among treatment arms. We will conduct a subgroup analyze to test whether the treatment effects differ among subgroups (N0, N1, M1a).

Endpoints

The primary endpoint is overall survival in all randomized patients. Overall survival is defined as time from the date of randomization until death. The secondary endpoint is progression free survival (PFS) and adverse events. PFS is defined as the time from the date of randomization to the date of progression or to the date of death, whichever occurs first and disease progression will be evaluated according to RECIST Version 1.1. Adverse events will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0).

Data collection

Participants will be seen at hospital or contacted by telephone, letters from randomization to the end of treatment cycle, then at Month 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54 and 60 after last treatment. Research staff at the hospitals will be expected to complete trial CRFs which record evidence of primary and secondary outcome measures.

Interim analysis

We plan to conduct two interim analyses. The first interim analysis will be conducted independently from the study group when half of the planned number of patients are enrolled and the second interim just after the planned patient accrual is completed. If the superiority of one of test arms is demonstrated with an adjusted α level, the study will be terminated.

In general, the interim reports will contain the following information:

1. Patient accrual rate with a projected completion date (while the study is still accruing)

2. Total patients accrued

3. Distributions of important pretreatment and prognostic baseline variables

4. The frequencies and severity of adverse events by treatment arm.

5. Compliance rates of treatment delivery

6. Observed results with respect to the primary and secondary endpoints

Patient and Public Involvement

Patients in this study will be recruited from the outpatient of participant centers. After diagnosis and necessary clinical assessment, this clinical trial will be introduced to the patients to get their approval. All the recruitment and conduct of this study will be the responsible for doctors and other staffs. The only obligation of patients is to report any discomfort during the process of this study. Trial results will be disseminated via peer reviewed scientific journals and conference presentations rather than specifically notified to a single patient. No extra financial burden for patients if they are enrolled in this trial because standard cost of three treatment plans are similar if patients covered by the same insurance.

Ethics and dissemination

This trial has been approved by the Fudan University Shanghai Cancer Center Institutional Review Board (Ethics Committee of Fudan University Shanghai Cancer Center: No.1505146-13). Written informed consent will be obtained from all participants. Serious adverse events will be reported to the safety desk of the trial, the Data and Safety Monitoring Board and trial sites. Trial results will be disseminated via peer reviewed scientific journals and conference presentations.

Participating institutions (From east to west)

BMJ Open

Fudan University Shanghai Cancer Center, Huadong Hospital Affiliated to Fudan
University, Fudan University Shanghai Cancer Center Minhang Branch, Affiliated
Hospital of Jiangnan University, Fujian Province Cancer Hospital, Jiangsu Province
Cancer Hospital, The First Affiliated Hospital of Xiamen University, Jiangxi Province
Cancer Hospital, Shanxi Province Cancer Hospital, Hainan Province People's
Hospital, Gansu Province Cancer Hospital

Trial Status

The trial was initiated in July 2015 and is currently recruiting patients in all of the participating institutions above.

Reference:

- 1. Torre LA, Bray F, Siegel RL, et al. Global Cancer Statistics, 2012. Ca-Cancer J Clin 2015;**65**(2):87-108.
- 2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;**349**(23):2241-52.
- Herskovic A, Martz K, Alsarraf M, et al. Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the Esophagus. New Engl J Med 1992;326(24):1593-98.
- 4. Ajani JA, Ilson DH, Daugherty K, et al. Activity of Taxol in Patients with Squamous-Cell Carcinoma and Adenocarcinoma of the Esophagus. J Natl Cancer I 1994;86(14):1086-91.
- 5. Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008;**26**(28):4551-56.
- 6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc 2001;24(1):91-95.

7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant
| | chemorationerapy plus surgery versus surgery alone for besophagea |
|---------|---|
| | junctional cancer (CROSS); long-term results of a randomised controll |
| | trial Lancet Oncol 2015: 16 (9):1090-98 |
| 8 Safr | an H Gaissert H Akerman P et al Paclitaxel cisplatin and concurrent |
| o. Sun | radiation for esonhageal cancer Cancer Invest 2001: 19 (1):1-7 |
| 9. Baiı | ns MS. Stojadinovic A. Minsky B. et al. A phase II trial of preoperative |
| | combined-modality therapy for localized esophageal carcinoma: Initia |
| | results. J Thorac Cardiov Sur 2002; 124 (2):270-77. |
| 10. Ur | ba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel |
| | radiotherapy as preoperative treatment for patients with locoregional |
| | esophageal carcinoma. Cancer 2003; 98 (10):2177-83. |
| 11. Lii | ۱ CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice |
| | weekly paclitaxel and cisplatin followed by esophagectomy for locally |
| | advanced esophageal cancer. Ann Oncol 2007; 18 (1):93-98. |
| 12. Ho | ning J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclita |
| | with cisplatinum and 5-fluorouracil in definitive chemoradiation in |
| | esophageal cancer patients. Ann Oncol 2014; 25 (3):638-43. |
| 13. Mo | ohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of |
| | definitive chemoradiation in patients with inoperable or irresectable |
| | esophageal carcinoma. Bmc Cancer 2014; 14 . |
| 14. La | katos E. Designing complex group sequential survival trials. Stat Med |
| | 2002; 21 (14):1969-89. |
| 15. La | katos E. Sample Sizes Based on the Log-Rank Statistic in Complex |
| | Clinical-Trials. Biometrics 1988; 44 (1):229-41. |

1	
2 3	Declarations
4	
5	
7	TP: Paclitaxel combined with cisplatin
8	TC: Paclitaxel combined with carboplatin
10	TF: Paclitaxel combined with fluorouracil
11 12	UICC: Union for International Cancer Control
13	ESCC: Esophageal squamous cell carcinoma
14 15	PF: Cisplatin combined with fluorouracil
16	AIDS: Acquired immune deficiency syndrome
17 18	RT: Radiotherapy
19 20	PTX: Paclitaxel
21	DDP: Cisplatin
22 23	CBP: Carboplatin
24 25	5-FU: Fluorouracil
26	W: Week
28	ICRU: International Commission on Radiation Units and Measurements
29 30	GTV: Gross Target Volume
31	CTV: Clinical Target Volume
32 33	PTV: Planning Target Volume
34 35	WBC: White Blood Cell
36	ANC: Absolute Neutrophil Counts
37 38	Hb: Hemoglobin
39	Plt: Platelet
40 41	ULN: Upper Limit of Normal
42	A ST: A granteta Transaminaga
43 44	AST. Aspartate transaminase
45	ALI: Alanine aminotransferase
46 47	
48	
49	Consent of publication
50 51	
52	Not applicable
53	
54	Declaration of interests
55 56	We dealers as compating interests
57	we declare no competing interests.
58	

Funding

The study was supported by 2015 Prospective Clinical Research Fund of Fudan University Shanghai Cancer Center.

Author's contributions

D Ai was responsible for drafting the manuscript. Y Chen, Q Liu, J Zhang, J Deng, H Zhu, W Ren, K Wu, M Fan, H Yang, Z Zhu, W Zhao, L Li were responsible for the collection of previous study and putting forward the conception. X Zheng, Y Li, J Ye, J Zhou, Q Lin, H Luo, J Cao, S Wei, J Fan, J Li, G Huang and H Badakhshi were responsible for designing the details of the study. K Zhao was responsible for all aspects of trial design, the protocol and trial conduct. All authors have read and approved this manuscript. Page 19 of 24

BMJ Open

1	
2	
3	Fig1. Treatment Design of the ESO-Shanghai 2 trial.
4 5	TP (arm A), TF (arm B) and TC (arm C) are TP-, TF- and TC-based definitive
6	chemoradiotherapy, respectively.
8	RT=radiotherapy PTX=paclitaxel DDP=cisplatin 5-Fu=fluorouracil
9	
10	CBP=carboplatin, W=Week.
11	
12	
14	
15	
16	
17	
19	
20	
21	
22	
24	
25	
26 27	
28	
29	
30	
31	
33	
34	
35	
37	
38	
39	
40 41	
42	
43	
44	
45 46	
47	
48	
49	
50 51	
52	
53	
54	
55 56	
57	
58	
59 60	For peer review only - http://bmiopen.bmi.com/site/about/quidelines.yhtml
UO	To peer review only integry on jopen.on j.com/ site/ about/ guidelines.Antim





STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

11 12 13	Section/item	ltem No	Description	Addressed on page number
14 15	Administrative inf	ormatior		
16 17	Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
18 19	Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
20 21		2b	All items from the World Health Organization Trial Registration Data Set	None
22	Protocol version	3	Date and version identifier	None
23 24 25	Funding	4	Sources and types of financial, material, and other support	17
25 26	Roles and	5a	Names, affiliations, and roles of protocol contributors	17
27 28	responsibilities	5b	Name and contact information for the trial sponsor	17
29 30 31 32		5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	None
 33 34 35 36 37 38 39 40 41 42 		5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	None
42 43 44				
45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

2				
3 4	Introduction			
5 6 7	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant	5
8		6b	Explanation for choice of comparators	6
9 10	Objectives	7	Specific objectives or hypotheses	6
 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6
	Methods: Participa	nts, int	erventions, and outcomes	
	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will _ be collected. Reference to where list of study sites can be obtained	13
	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	6-7
	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	9
26 27 28		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	10
29 30 31		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	None
32 33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	9
34 35 36 37 38	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, _ median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	12
39 40 41	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for _ participants. A schematic diagram is highly recommended (see Figure)	12
42 43 44 45 46 47			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined including	12
3 4			clinical and statistical assumptions supporting any sample size calculations	' <i>`</i>
5 6 7	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	None
8 9	Methods: Assignm	ent of ir	nterventions (for controlled trials)	
10	Allocation:			
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	11
	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered,	11
	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to	11
	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome	None
		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	None
31 32	Methods: Data coll	ection,	management, and analysis	
33 34 35 36 37	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related	11
38 39 40 41		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be	None
42 43 44 45 46 47			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	3

2 3 4 5	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	None
6 7 8	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the _ statistical analysis plan can be found, if not in the protocol	12
9 10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	12
11 12 13 14		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	None
15 16	Methods: Monitorin	g		
17 18 19 20 21	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	None
22 23 24		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim _ results and make the final decision to terminate the trial	12
25 26 27	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	11
28 29 30	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	None
31 32 33	Ethics and dissemi	nation		
34 35 36	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	13
37 38 39 40 41 42	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	None
43 44 45 46 47			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	4

BMJ Open

1 ว					
2 3 4 5 6 7 8 9 10 11 12 13	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	None	
		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary	None	
	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	None	
	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	17	
14 15 16	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	None	
17 18 19 20 21 22 23	Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	None	
	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals,	None	
24 25		31b	Authorship eligibility guidelines and any intended use of professional writers	None	
26 27 28 29 30 31 32 33 34 35 26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	None	
	Appendices				
	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	None	
	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	None	
37 38 39 40 41	*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons " <u>Attribution-NonCommercial-NoDerivs 3.0 Unported</u> " license.				
42 43 44 45 46 47			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	5	

BMJ Open

Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2)

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-020785.R2
Article Type:	Protocol
Date Submitted by the Author:	05-May-2018
Complete List of Authors:	 Ai, Dashan; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Chen, Yun; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Liu, Qi; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhang, Junhua; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Deng, Jiaying; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Deng, Jiaying; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhu, Hanting; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Ren, Wenjia; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhuang, Xiangpeng; Huadong Hospital Affiliated to Fudan University, Department of Radiation Oncology Zhunhai; Fudan University Shanghai Cancer Center Minhang Branch Hospital, Department of Radiation Oncology Wei, Shihong; Gansu Province Cancer Hospital, Department of Radiation Oncology Ye, Jinjun; Jiangsu Cancer Hospital, Department of Radiation Oncology Lin, Qin; First Affiliated Hospital of Xiamen University, Department of Radiation Oncology Lin, Qin; First Affiliated Hospital of Xiamen University, Department of Radiation Oncology Lin, Univ; Jiangxi Province Cancer Hospital, Department of Radiation Oncology Lin, Univ; Jiangxi Province Cancer Hospital,

	 Nuality, Guality, Halinan Province People's hospital, Department of Radiation Oncology Wu, Kailiang; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Fan, Min; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Yang, Huanjun; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhu, Zhengfei; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhu, Zhengfei; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhao, Weixin; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Li, Ling; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Li, Ling; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Fan, Jianhong; Renhe Hospital, Department of Gynecology Badakhshi, Harun; Charite ' School of Medicine and Centre for Cancer Medicine, Department of Radiation Oncology Zhao, Kuaile; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Radiation Oncology
Primary Subject Heading :	Oncology
Secondary Subject Heading:	Oncology
Keywords:	esophageal squamous cell carcinoma, concurrent chemoradiotherapy,



Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2) Dashan Ai^{1, 2}, Yun Chen^{1, 2}, Qi Liu^{1, 2}, Junhua Zhang^{1, 2}, Jiaying Deng^{1, 2}, Hanting Zhu^{1, 2}, Wenjia Ren^{1, 2}, Xiangpeng Zheng³, Yunhai Li⁴, Shihong Wei⁵, Jinjun Ye⁶, Jialiang Zhou⁷, Qin Lin⁸, Hui Luo⁹, Jianzhong Cao¹⁰, Jiancheng Li¹¹, Guang Huang¹², Kailiang Wu^{1, 2}, Min Fan^{1, 2}, Huaniun Yang^{1, 2}, Zhengfei Zhu^{1, 2}, Weixin Zhao^{1, 2}, Ling Li^{1, 2}, Jianhong Fan¹³, Harun Badakhshi¹⁴, Kuaile Zhao^{1, 2} 1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China 3. Department of Radiation Oncology, Huadong Hospital Affiliated to Fudan University, Shanghai, China 4. Department of Radiation Oncology, Fudan University Shanghai Cancer Center Minhang Branch Hospital, Shanghai, China 5. Department of Radiation Oncology, Gansu Province Cancer Hospital, Lanzhou, China 6. Department of Radiation Oncology, Jiangsu Province Cancer Hospital, Nanjing, China 7. Department of Radiation Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China 8. Department of Radiation Oncology, First Affiliated Hospital of Xiamen University, Xiamen, China 9. Department of Radiation Oncology, Jiangxi Province Cancer Hospital, Nanchang, China 10. Department of Radiation Oncology, Shanxi Province Cancer Hospital, Taiyuan, China 11. Department of Thoracic Radiation Oncology, Fujian Province Cancer Hospital, Fuzhou, China 12. Department of Radiation Oncology, Hainan Province People's Hospital, Haikou, China

60

BMJ Open

1	
2	
4	13. Department of Gynecology, Renhe hospital, Shanghai, China
5	14. Department of Radiation Oncology, Charite' School of Medicine and Centre for
6 7	Cancer Medicine, Berlin, Germany
8	Corresponding author: Kuaile Zhao, 270 Dongan Rd, Shanghai, 200032, China. Email:
9 10	kuaile z@shca.org.cn. Tel: +86-21-64175590
11	Key words: esophageal squamous cell carcinoma concurrent chemoradiotherapy
12 13	naclitaxel cisplatin carbonlatin fluorouracil
14	puentuxei, eisplatin, eurooplatin, nuorouraen
15	Word counts: 2,856 words
16	
17	
18	
19	
20	
22	
23	
24	
25	
26	
27	
28	
29	
30	
37	
33	
34	
35	
36	
37	
38	
39	
40 41	
47	
43	
44	
45	
46	
47	
48	
49 50	
51	
52	
53	
54	
55	
56	
57	
58	2

Abstract

Introduction: Concurrent chemoradiation is the standard therapy for patients with local advanced esophageal carcinoma unsuitable for surgery. Paclitaxel is an active agent against esophageal cancer and it has been proved as a potent radiation sensitizer. There have been multiple studies evaluating paclitaxel-based chemoradiation in esophageal cancer, the results of which are inspiring. However, which regimen, among paclitaxel in combination with cisplatin (TP), carboplatin (TC) and fluorouracil (TF) concurrent with radiotherapy, provides best prognosis with minimum adverse events is still considered far from resolved and very few studies focus on this field. The purpose of this study is to confirm the priority of TF to TP or TC concurrent with radiotherapy in terms of overall survival and propose a feasible and effective plan for patients with local advanced esophageal cancer. Methods and analysis: ESO-Shanghai 2 is a three-arm, multicenter, open-labeled, randomized phase III clinical trial. The study was initiated in July 2015 and the duration of inclusion will be 4 years. The study compares two pairs of regimen: TF versus TP and TF versus TC concurrent with definitive radiotherapy for patients with esophageal squamous cell carcinoma (ESCC). Patients with histologically confirmed ESCC (clinical stage II, III or IVa based on the 6th UICC-TNM classification) and without any prior treatment of chemotherapy, radiotherapy or surgery against esophageal cancer will be eligible. A total of 321 patients will be randomized and allocated in a 1:1:1 ratio to the three treatment groups. Patients are stratified by lymph node status (N0, N1, M1a). The primary endpoint is overall survival and the secondary endpoint is progression-free survival and adverse events. Ethics and dissemination:

This trial has been approved by the Fudan University Shanghai Cancer Center Institutional Review Board. Trial results will be disseminated via peer reviewed scientific journals and conference presentations.

Trial registration: Clinicaltrials.gov: NCT02459457

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1	
2	
3	Strengths and limitations of this study
5	• First phase III randomized multi-centered study comparing these three regimens
6 7	• Stratification by lymph node status (N0, N1, M1a based on the 6 th UICC-TNM
8	classification)
9 10	• No stratification for different centers
11	
12 13	
14	
15	
17	
18	
20	
21	
22	
23	
25	
26 27	
28	
29	
31	
32	
33 34	
35	
36	
38	
39	
40 41	
42	
43 44	
45	
46	
47 48	
49	
50 51	
52	
53 54	
54 55	
56	
57 58	
59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Introduction

Worldwide, esophageal cancer is the eighth most common cancer, which is responsible for an estimated 455,800 new cases and 400,200 deaths in 2012.¹ Since its prognosis is dismal, much effort has been put into improving overall survival through multi-modality treatments, which consist of surgery, radiotherapy and chemotherapy.² Concurrent chemoradiation is the standard non-operative therapy for local advanced esophageal squamous cell carcinoma (ESCC).³

Paclitaxel is an active agent against esophageal cancer, with the response rate of 28% in ESCC, and it has been shown to be a potent radiation sensitizer.⁴ There have been multiple studies evaluating paclitaxel-based chemoradiation in esophageal cancer, for instance, paclitaxel/fluorouracil (TF) developed at The University of Texas M.D. Anderson Cancer Center, and paclitaxel/cisplatin (TP) developed at Memorial Sloan-Kettering Cancer Center, ⁵⁶ with paclitaxel/carboplatin (TC) from CROSS trial.⁷ In many preoperative studies, paclitaxel-based chemoradiotherapy has achieved inspiring effect, the pathologic complete response rates of TP-based chemoradiotherapy were 19%-42%, ⁸⁻¹¹ and of TC-based chemoradiotherapy was 49%.⁷ However, which regimen, among TF, TP and TC-based definitive chemoradiotherapy, provides best prognosis with minimum adverse events is still considered far from resolved and very few studies focus on this field.

RTOG 0113⁵ evaluated 2 different paclitaxel-based regimens (TP and TF). Eighty-four patients were accrued to this study. Patients in arm A (TF) received induction 5-FU, cisplatin, and paclitaxel followed by radiation and concurrent continuous infusion 5-FU and weekly paclitaxel. Patients in arm B (TP) received induction paclitaxel and cisplatin followed by radiation and concurrent weekly cisplatin and 96-hour infusion of paclitaxel. The median survival time was 28.7 months for patients in arm A (TF) and 14.9 months for patients in arm B (TP). Neither arm achieved the hypothesized 1-year survival rate of at least 77.5%. The main deficiency of this study is the small sample size, but the effect of TF group is still inspiring.

Another retrospective multicenter randomize clinical trials from Europe¹² showed the overall survival of TC-based definitive chemoradiotherapy was comparable with cisplatin/5-FU (PF) as definitive concurrent chemoradiotherapy in

esophageal cancer. However, the toxicity rates were lower in the TC group together with higher treatment compliance.

Based on RTOG 0113 and other reports, we designed a multicenter randomized controlled phase III trial to confirm the priority of TF to TP and TF to TC concurrent with radiotherapy in terms of overall survival for patients with local advanced esophageal squamous cell carcinoma. Independent ethics committees of the participating centers approved the study protocol. This trial has been registered with ClinicalTrials.gov, number NCT02459457.

The trial is a three-arm, multicenter, open-labeled, randomized phase III clinical trial. The study was initiated in July 2015 and the duration of inclusion will be 4 years. The study compares two pairs of regimen: TF versus TP and TF versus TC concurrent with definitive radiotherapy in patients with esophageal squamous cell carcinoma.

Methods and analysis

Patient selection

To be eligible for this study, patient must fulfill all of the following criteria (Table 1):

Inclusion criteria

- 1. Histologically confirmed esophageal squamous cell carcinoma
- 2. Clinical stages II, III or IVa based on the 6th UICC-TNM classification
- 3. No prior treatment of chemotherapy, radiotherapy or surgery against esophageal cancer, except for non-curative resection by EMR/ESD.
- 4. Aged 18-75 years
- 5. Adequate organ functions for chemoradiation therapy
 - a) White blood cell (WBC) $\geq 3 \times 10^{9}$ /L
 - b) Absolute neutrophil counts (ANC) $\geq 1.5 \times 10^{9}/L$
 - c) Hemoglobin (Hb) $\geq 10g/dl$
 - d) Platelet (Plt) $\geq 100 \times 10^{9}$ /L
 - e) Total bilirubin <1.5 upper limit of normal (ULN)
 - f) Aspartate transaminase (AST) ≤ 2.5 ULN
 - g) Alanine aminotransferase (ALT) ≤ 2.5 ULN

2	
ر ۸	
4	
5	
6	
7	
8	
9	
10	
11	
12	
12	
13	
14	
15	
16	
17	
18	
19	
20	
20	
ו∡ 20	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
27	
22	
33	
34	
35	
36	
37	
38	
39	
40	
<u>д</u> 1	
יד ⊿2	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
57	
52	
22	
54	
55	
56	
57	
58	
59	
60	

h) Creatinine ≤ 1.5 ULN

6. ECOG PS of 0-2

7. Life expectancy \geq 3 months

8. Written informed consent (Supplementary material)

Table 1. Inclusion criteria

Patients fulfilling any of the following criteria are ineligible for this study (Table 2).

Exclusion criteria

1. Esophageal perforation or hematemesis

2. Synchronous or metachronous malignancies (except for cutaneous (non-melanomas) carcinoma, thyroid papillary carcinoma, phase I seminoma or cervical carcinoma in situ curatively treated and disease free for a minimum of 3 months)

3. Received thoracic, abdominal or craniocerebral surgery within 30 days

4. Enrolled in other clinical trials within 30 days

5. Unstable angina and/or congestive heart failure requiring hospitalization within 6 months

6. Severe psychiatric disease

7. Pregnancy, lactation or unwillingness to adopt contraception

8. Drug addiction

9. Acquired immune deficiency syndrome (AIDS) based upon current CDC definition

10. History of radiotherapy in the planning area

11. Other ineligible conditions according to researchers

Table 2. Exclusion criteria

Treatment

The treatment plan is shown in Figure 1. Patients receive radiotherapy combined with concurrent chemotherapy. Radiotherapy begins on day 1, concurrent with the beginning of cycle 1 of chemotherapy.

Same radiation therapy will be delivered in all three treatment groups. Radiotherapy is delivered with photons (≥ 6 MV) to a total dose of 61.2Gy in 34 fractions. Patients will be treated 5 days per week at 1.8Gy/d. Three-dimensional

BMJ Open

conformal radiotherapy or intensity modulated radiotherapy is required. All patient will be positioned in an individualized immobilization device in the treatment position.

The definition of volumes will be in accordance with the 1993 ICRU Report #50 and 1999 ICRU Report #62.

The gross target volume (GTV) is defined as all known involved field, which detected by endoscopic ultrasound, barium swallow or CT scan (whichever is larger). The regional lymph nodes included in GTV is whose diameter more than 1cm (0.5cm for lymph nodes at tracheoesophageal groove) or histologically proven metastatic after puncture.

The superior and inferior borders of the clinical target volume (CTV) are 3cm beyond the primary tumor along the esophagus. The lateral, anterior and posterior borders of the field are the same as GTV.

The superior, inferior, anterior, posterior and lateral borders of planning target volume (PTV) are 1cm beyond CTV. Field next to the spinal cord could be slightly adjusted in order to reduce the exposure of spinal cord.

As for target volume, tissue inhomogeneity correction is adopted and it is required that more than 99% PTV receive 95% prescription dose and more than 95% PTV receive 99% or more prescription dose. Highest and lowest point dose inside PTV should be recorded.

When making the treatment plan, we should take normal organ dose restrictions into consideration as the following order: (Table 3)

Risk organ	Contour regulation	Dose restriction
Spinal cord	All the layers of CT scan have	Highest point dose less
	to be contoured and the margin	than 45Gy
	of vertebra tube can be	
	regarded as that of planning	
	organ at risk volume.	
Lung	It is allowed to use automatic	The volume of lung (PTV
	tools in the delineation of	excluded) receiving 20Gy
	margin of lungs. (Trachea and	or higher has to be less

1	
2	
3	
4	
5	
6	
7	
, 0	
0	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
20	
∠ ı วว	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
25	
26	
30	
3/	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
<u>م</u> ک	
50	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	

	bronchia must be contoured	than 30% of the total lung
	manually)	volume, and the mean
		dose has to be less than
		15Gy.
Heart	The superior margin of heart	The mean dose has to be
	consists of right atrium and	less than 40Gy.
	right ventricle, pulmonary	
	artery trunk, ascending main	
	aorta and superior vena cava	
	excluded. The inferior margin	
	is at the level of heart apex.	
· · · · · · · · · · · · · · · · · · ·	<u> </u>	

Table 3. Contour regulation and dose restriction of risk organs

Chemotherapy

Patients are randomly assigned to receive one of three therapies.

Arm A (TP)

Patients in arm A receive 4 courses of TP every 4 weeks. Details are as follows:

Paclitaxel: 175mg/m²/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m²/d, ivgtt, d1-3;

Arm B (TF)

Patients in arm B receive 6 courses of TF concurrent with radiotherapy every week and 2 courses of TF consolidation chemotherapy every 4 weeks. Details are as follows:

Concurrent: paclitaxel 50mg/m²/d, ivgtt over 3 hours, d1; 5-FU 300mg/m², civ 96h, d1-4

Consolidation: paclitaxel 175 mg/m²/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m², civ 72h, d1-3

Arm C (TC)

Patients in arm C receive 6 courses of TC concurrent with radiotherapy every week and 2 courses of TC consolidation chemotherapy every 4 weeks. Details are as follows:

Concurrent: paclitaxel 50mg/m²/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1

Consolidation: paclitaxel 175 mg/m²/d, ivgtt over 3 hours, d1; carboplatin AUC=5,

1	
2 3	ivett dl
4	Detients receive premedication to prevent allergic reaction and significant payses or
5 6	Tatients receive preniedication to prevent anergic reaction and significant nausea of
7	vomiting as indicated.
8	
10	Dose modifications
11	Radiotherapy interruption
12	If following toxicity is observed radiotherapy has to be delayed until toxicity is no
14	more then grade 2
15 16	
17	• WBC< 2.0×10^{2} /L or ANC< 1.0×10^{2} /L
18	• $Plt < 50 \times 10^9/L$
20	• Grade 3 or higher non-hematological toxicity
21	If following toxicity is observed, radiotherapy has to be delayed until complete
22	recovery.
24	• Mediactinal or thoracic infection with favor over 38.5
25 26	
27	It is allowed to suspend at most 2 weeks, or radiotherapy will be terminated.
28	
30	Chemotherapy interruption and dose modifications
31	If following toxicity is observed on day 1, chemotherapy has to be delayed until
32 33	toxicity is no more than grade 1.
34	• $ANC < 1.5 \times 10^9 / I$
35 36	 Alle <1.5×10 /L Db <100 / L
37	• PII<100×10 /L
38 30	• Grade 2 or higher non-hematological toxicity, except for nausea, vomiting and
40	alopecia
41	It is allowed to delay at most 2 weeks, or chemotherapy will be terminated.
42	Chemotherapy dose modifications are based on the greatest toxicity during the last
44	cycle. Any patients who need to make chemotherapy dose modifications will receive
45 46	the modified does in the following avalue
47	the modified dose in the following cycles.
48 49	If modifications are needed, dose of paclitaxel, cisplatin, carboplatin and 5-FU will
50	decreased by 25% from the planned dose for the first time and 50% for the second
51	time. It is allowed to make dose modifications at most twice, or chemotherapy will be
52 53	terminated. Details are as follows:
54	Dose modification of paclitaxel
55 56	• Exprise neutropenia (ANC< 0.5×10^{9} /L and favor over 28.2 \Box or over 28.0 \Box for
57	• refine neuropenia (Anc $> 0.5 \land 10$ /L and level over $50.5 \square$ of over $58.0 \square$ 101
58 59	10
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1h)

• Grade 2 or higher peripheral neuropathy

Dose modification of cisplatin and carboplatin

• Febrile neutropenia (ANC< 0.5×10^{9} /L and fever over 38.3 or over 38.0 for

1h)

- Grade 2 or higher peripheral neuropathy
- Serum creatinine >3ULN

Dose modification of 5-FU

• Febrile neutropenia (ANC< 0.5×10^9 /L and fever over $38.3 \square$ or over $38.0 \square$ for 1h)

• Grade 3 or higher mucositis

The adverse events will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0). All adverse events, occurring during the course of the trial, which is from randomization until 28 days after end of treatment, regardless of relatedness to study medication, will be recorded. Adverse events occurring later than 28 days after the end of treatment will only be recorded if they are considered relevant.

Randomization

After the confirmation of eligibility criteria, patients will be randomly allocated in a 1:1:1 ratio to the three treatment groups by a central randomization center (Fudan University Shanghai Cancer Center, Shanghai, China). Patients will be stratified by lymph node status (N0, N1, M1a). The SAS was used to generate a random permutation sequence and produce patient randomization numbers. The data center registers the enrollment, assigns a unique identification number to every participant, and replies to the respective investigators.

Sample size calculation and statistical analysis

This three-arm randomized trial is designed to confirm whether TF is superior to TP or TC concurrent with radiotherapy in terms of overall survival. According to RTOG

BMJ Open

0113 and other reports, median survival time of TF concurrent with radiotherapy for esophageal cancer is 28.7 months while TP 14.9 months⁵ and TC 17.4 months¹³. According to the Schoenfeld and Richter's method, the sample size of 107 patients per arm (154 events in total) is required to warrant a power of 80% at a two-sided α level of 0.025 for the comparison between TP and TF with relatively smaller difference, assuming an accrual period of 48 months, a minimum follow-up period of 24 months and a dropout rate of $10\%^{14}$ ¹⁵. The total sample size is planned as 321 patients (107 patients in each arm, a total of 231 events).

The median overall survival will be estimated with Kaplan-Meier method, and log-rank test will be used to compare the overall survival among treatment arms. We will conduct a subgroup analyze to test whether the treatment effects differ among subgroups (N0, N1, M1a).

Endpoints

The primary endpoint is overall survival in all randomized patients. Overall survival is defined as time from the date of randomization until death. The secondary endpoint is progression free survival (PFS) and adverse events. PFS is defined as the time from the date of randomization to the date of progression or to the date of death, whichever occurs first and disease progression will be evaluated according to RECIST Version 1.1. Adverse events will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0).

Data collection

Participants will be seen at hospital or contacted by telephone, letters from randomization to the end of treatment cycle, then at Month 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54 and 60 after last treatment. Research staff at the hospitals will be expected to complete trial CRFs which record evidence of primary and secondary outcome measures.

Interim analysis

We plan to conduct two interim analyses. The first interim analysis will be conducted independently from the study group when half of the planned number of patients are enrolled and the second interim just after the planned patient accrual is completed. If the superiority of one of test arms is demonstrated with an adjusted α level, the study will be terminated.

In general, the interim reports will contain the following information:

1. Patient accrual rate with a projected completion date (while the study is still accruing)

2. Total patients accrued

3. Distributions of important pretreatment and prognostic baseline variables

4. The frequencies and severity of adverse events by treatment arm.

5. Compliance rates of treatment delivery

6. Observed results with respect to the primary and secondary endpoints

Patient and Public Involvement

Neither patients nor public will be involved in the design, recruitment, outcome measures and conduct of the study. Trial results will be disseminated via peer reviewed scientific journals and conference presentations rather than specifically notified to a single patient. 12.0

Ethics and dissemination

This trial has been approved by the Fudan University Shanghai Cancer Center Institutional Review Board (Ethics Committee of Fudan University Shanghai Cancer Center: No.1505146-13). Written informed consent will be obtained from all participants. Serious adverse events will be reported to the safety desk of the trial, the Data and Safety Monitoring Board and trial sites. Trial results will be disseminated via peer reviewed scientific journals and conference presentations.

Participating institutions (From east to west)

Fudan University Shanghai Cancer Center, Huadong Hospital Affiliated to Fudan University, Fudan University Shanghai Cancer Center Minhang Branch, Affiliated Hospital of Jiangnan University, Fujian Province Cancer Hospital, Jiangsu Province Cancer Hospital, The First Affiliated Hospital of Xiamen University, Jiangxi Province Cancer Hospital, Shanxi Province Cancer Hospital, Hainan Province People's Hospital, Gansu Province Cancer Hospital

Page 15 of 29	BMJ Open
1 2 3 4 5 6 7 8 9 10 11	Trial Status The trial was initiated in July 2015 and is currently recruiting patients in all of the participating institutions above.
12 13 14 15 16	Reference: 1. Torre LA, Bray F, Siegel RL, et al. Global Cancer Statistics, 2012. Ca-Cancer J Clin
18 19 20	2015; 65 (2):87-108. 2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med
21 22 23 24 25	2003; 349 (23):2241-52. 3. Herskovic A, Martz K, Alsarraf M, et al. Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer
26 27 28 29 30	of the Esophagus. New Engl J Med 1992; 326 (24):1593-98. 4. Ajani JA, Ilson DH, Daugherty K, et al. Activity of Taxol in Patients with Squamous-Cell Carcinoma and Adenocarcinoma of the Esophagus. J Natl
31 32 33 34	Cancer I 1994; 86 (14):1086-91. 5. Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two
35 36 37 38 39	chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008; 26 (28):4551-56.
40 41 42 43	6. Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol-Canc
44 45 46 47 48	2001; 24 (1):91-95. 7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or
49 50 51 52	junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015; 16 (9):1090-98.
55 55 56 57	radiation for esophageal cancer. Cancer Invest 2001; 19 (1):1-7. 9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative
58 59 60	14 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiov Sur 2002;124(2):270-77. 10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177-83. 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98. 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43. 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;14. 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;**21**(14):1969-89. 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41.

2	
3	Declarations
5	List of abbreviations
6	TP: Paclitaxel combined with cisplatin
8	TC: Paclitaxel combined with carboplatin
9	TE: Paclitavel combined with fluorouracil
11	LUCC: Union for International Concer Control
12	
13	ESCC: Esophageal squamous cell carcinoma
15	PF: Cisplatin combined with fluorouracil
16 17	AIDS: Acquired immune deficiency syndrome
18	RT: Radiotherapy
19 20	PTX: Paclitaxel
21	DDP: Cisplatin
22 23	CBP: Carbonlatin
24	
25 26	S-FO: Fluorourach
27	W: Week
28	ICRU: International Commission on Radiation Units and Measurements
30	GTV: Gross Target Volume
31	CTV: Clinical Target Volume
33	PTV: Planning Target Volume
34	WBC: White Blood Cell
35 36	ANC: Absolute Neutrophil Counts
37	
38 39	Hb: Hemoglobin
40	Plt: Platelet
41 42	ULN: Upper Limit of Normal
43	AST: Aspartate Transaminase
44 45	ALT: Alanine aminotransferase
46	
47 48	
49	Consent of publication
50 51	
52	Not applicable
53	
55	Declaration of interests
56	We declare no competing interests.
57 58	

Funding

The study was supported by 2015 Prospective Clinical Research Fund of Fudan University Shanghai Cancer Center.

Author's contributions

D Ai was responsible for drafting the manuscript. Y Chen, Q Liu, J Zhang, J Deng, H Zhu, W Ren, K Wu, M Fan, H Yang, Z Zhu, W Zhao, L Li were responsible for the collection of previous study and putting forward the conception. X Zheng, Y Li, J Ye, J Zhou, Q Lin, H Luo, J Cao, S Wei, J Fan, J Li, G Huang and H Badakhshi were responsible for designing the details of the study. K Zhao was responsible for all aspects of trial design, the protocol and trial conduct. All authors have read and approved this manuscript.

Data Sharing Statement

No additional unpublished data from the study are available.

1 2 3 4 5 6 7	Fig1. Treatment Design of the ESO-Shanghai 2 trial. TP (arm A), TF (arm B) and TC (arm C) are TP-, TF- and TC-based definitive chemoradiotherapy, respectively.
8	RT=radiotherapy, PTX=paclitaxel, DDP=cisplatin, 5-Fu=fluorouracil,
10	CBP=carboplatin, W=Week.
11	
12 13	
14	
15 16	
17	
18 10	
20	
21	
22 23	
24	
25 26	
27	
28 29	
30	
31 32	
33	
34 35	
36	
37 38	
39	
40	
41 42	
43	
44 45	
46	
47 48	
49	
50 51	
52	
53 54	
55	
56 57	
58	
59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



Fig1. Treatment design of the ESO-Shanghai 2 trial. $| \top | RT$ =radiotherapy, PTX=paclitaxel, DDP=cisplatin, 5-Fu=fluorouracil, CBP=carboplatin, W=Week. $| \top |$

335x236mm (72 x 72 DPI)

1 2 3	
4 5	Com
6	fluo
/ 8	950
9	630
10 11	
12	
13	You
14 15	your
16	stud
17 18	Vou
19	Tou
20	esop
21	
23	Why
24 25	Cond
26	esop
27 28	8500
29	esop
30 21	been
32	canc
33	in co
34 35	with
36	cons
37 38	this s
39	1113 0
40	term
41 42	local
43	
44 45	How
46	Abou
47	
40 49	
50	wna
51 52	You
53	TP o
54 55	Radi
56	chen
57	
20	

60

Informed Consent Form

Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2)

You are being asked to take part in a clinical study. Please take your time to make your decision about taking part. If you have any questions, you can ask your study doctor for more explanation.

You are being asked to take part in this study because you have local advanced esophageal squamous cell carcinoma.

Why is this study being done?

Concurrent chemoradiation is the standard therapy for patients with local advanced esophageal carcinoma unsuitable for surgery. Paclitaxel is an active agent against esophageal cancer and it has been proved as a potent radiation sensitizer. There have been multiple studies evaluating paclitaxel-based chemoradiation in esophageal cancer, the results of which are inspiring. However, which regimen, among paclitaxel in combination with cisplatin (TP), carboplatin (TC) and fluorouracil (TF) concurrent with radiotherapy, provides best prognosis with minimum adverse events is still considered far from resolved and very few studies focus on this field. The purpose of this study is to confirm the priority of TF to TP or TC concurrent with radiotherapy in terms of overall survival and propose a feasible and effective plan for patients with local advanced esophageal cancer.

How many people will take part in the study?

About 321 people will take part in this study.

What will happen if I take part in this research study?

You will be randomized and allocated in a 1:1:1 ratio to the three treatment groups (TF, TP or TC). You will receive radiotherapy combined with concurrent chemotherapy. Radiotherapy will begin on day 1, concurrent with the beginning of cycle 1 of chemotherapy. Radiation therapy

Same radiation therapy will be delivered in all three treatment groups. Radiotherapy will be delivered with photons (\geq 6 MV) to a total dose of 61.2Gy in 34 fractions. You will be treated 5 days per week at 1.8Gy/d.

Chemotherapy

Arm A (TP)

If you are in arm A, you will receive 4 courses of TP every 4 weeks. Details are as follows:

Paclitaxel: 175mg/m²/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m²/d, ivgtt, d1-3; Arm B (TF)

If you are in arm B, you will receive 6 courses of TF concurrent with radiotherapy every week and 2 courses of TF adjuvant chemotherapy every 4 weeks. Details are as follows:

Concurrent: paclitaxel 50mg/m²/d, ivgtt over 3 hours, d1; 5-FU 300mg/m², civ 96h, d1-4

Adjuvant: paclitaxel 175 mg/m²/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m², civ 72h,

d1-3

Arm C (TC)

If you are in arm C, you will receive 6 courses of TC concurrent with radiotherapy every week and 2 courses of TC adjuvant chemotherapy every 4 weeks. Details are as follows:

Concurrent: paclitaxel 50mg/m²/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1 Adjuvant: paclitaxel 175 mg/m²/d, ivgtt over 3 hours, d1; carboplatin AUC=5, ivgtt, d1

During each treatment, blood tests will be performed to monitor blood counts, kidney function, liver function and electrolyte levels. Ultrasound, barium swallow and CT scan with contrast will be performed to evaluate the status of disease.

How long will I be in the study?

After your treatment is completed, you will be seen in follow-up visits with your doctor every 3 months in years 1-2, every 6 months in years 3-5 and then once a year for your lifetime.

Can I stop being in the study?

Yes. You can decide to stop at any time. Tell the study doctor if you are thinking about stopping or decide to stop. He or she will tell you how to stop safely.

It is important to tell the study doctor if you are thinking about stopping so he or she can evaluate any risks from the treatment. Another reason to tell your study doctor that you are thinking about stopping is to discuss what follow-up care and testing could be most helpful for you.

The study doctor may stop you from taking part in this study at any time if he/she believes it is in your best interest, if you do not follow the study rules, or if the study is stopped.

What side effects or risks can I expect from being in the study?

You may have side effects while on the study. Everyone taking part in the study will be watched carefully for any side effects. However, doctors don't know all the side effects that may happen. Side effects may be mild or very serious. There also is a risk of death.

Risks and side effects related to the chemoradiotherapy

- Soreness in throat or esophagus
- Cough
- Vomiting
- Nausea
- Fatigue
- Anorexia (loss of appetite)
- Diarrhea
- Numbness in arms and legs
- Allergic reaction
- Hair loss
- Redness of irritation of the skin in the treatment area
- Decrease in white blood cell counts and high risk of infection
- Renal insufficiency,

Are there benefits to taking part in the study?

Taking part in this study may or may not make your health better. While researchers hope these treatment regimens will be more useful against cancer compared to the usual treatment, there is no proof of this yet. We do know that the information from this study will help researchers learn more about these combinations of drugs as a treatment for cancer. This information could help future cancer patients.

Will my medical information be kept private?

We will do our best to make sure that the personal information in your medical record will be kept private. Your personal information may be given out if required by law. If information from this study is published or presented at scientific meetings, your name and other personal information will not be used.

What happens if I am injured because I took part in this study?

It is important that you tell your study doctor if you feel that you have been injured because of taking part in this study. You will get medical treatment if you are injured as a result of taking part in this study. You and/or your health plan will be charged for this treatment. The study will not pay for medical treatment.

What are my rights if I take part in this study?

Taking part in this study is your choice. You may choose either to take part or not to take part in the study. If you decide to take part in this study, you may leave the study at any time. No matter what decision you make, there will be no penalty to you and you will not lose any of your regular benefits. Leaving the study will not affect your medical care. You can still get your medical care from our center.

We will tell you about new information or changes in the study that may affect your health or your willingness to continue in the study.

In the case of injury resulting from this study, you do not lose any of your legal rights to seek payment by signing this form.

WHO CAN ANSWER MY QUESTIONS ABOUT THE STUDY?

You can talk to your study doctor about any questions or concerns you have about this study. Contact your study doctor, Kuaile Zhao, at 021-64175590.

Signature

I have been given a copy of all 5 pages of this form. I have read it or it has been read to me. I understand the information and have had my questions answered. I agree to take part in this study.

Participant:		
Name of Participant	Signature	Date
Researcher:		
Name of Participant	Signature	Date


45 46 47

SPIRIT STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Administrative informat	'n	
Title 1		
	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration 2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
2b	All items from the World Health Organization Trial Registration Data Set	None
Protocol version 3	Date and version identifier	None
Funding 4	Sources and types of financial, material, and other support	17
Roles and 5a	Names, affiliations, and roles of protocol contributors	17
responsibilities 5b	Name and contact information for the trial sponsor	17
5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	None
5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	None

1 2				
3 4	Introduction			
5 6 7 8 9 10 11 12 13	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant _ studies (published and unpublished) examining benefits and harms for each intervention	5
		6b	Explanation for choice of comparators	6
	Objectives	7	Specific objectives or hypotheses	6
	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6
15 16	Methods: Participa	nts, inte	erventions, and outcomes	
17 18 19	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will _ be collected. Reference to where list of study sites can be obtained	13
20 21 22 23 24 25 26 27 28 20	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	6-7
	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be _ administered	9
		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose _ change in response to harms, participant request, or improving/worsening disease)	10
29 30 31		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence _ (eg, drug tablet return, laboratory tests)	None
32 33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	9
34 35 36 37 38	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, _ median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	12
39 40 41	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for _ participants. A schematic diagram is highly recommended (see Figure)	12
42 43 44 45 46 47			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

2 3 4	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	12	
5 6 7	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	None	
8	Methods: Assignm	ent of i	nterventions (for controlled trials)		
9 10	Allocation:				
11 12 13 14 15 16	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	11	
17 18 19 20	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered,	11	
21 22 23	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to	11	
24 25 26	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	None	
27 28 29 30		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	None	
31 32	Methods: Data coll	ection,	management, and analysis		
32 33 34 35 36 37	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related	11	
38 39 40 41		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be	None	
42 43 44 45 46 47			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		3

1 ว				
2 3 4 5	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality _ (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	None
6 7 8	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the _ statistical analysis plan can be found, if not in the protocol	12
9 10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	12
11 12 13 14		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	None
15 16	Methods: Monitorin	g		
17 18 19 20 21	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	None
22 23 24		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim _ results and make the final decision to terminate the trial	12
25 26 27	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	11
28 29 30	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	None
31 32	Ethics and dissemi	nation		
33 34 35	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	13
37 38 39 40 41 42	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	None
43 44 45 46 47			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	4

2 3 4	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	None
5 6 7		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary _ studies, if applicable	None
8 9 10	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained _ in order to protect confidentiality before, during, and after the trial	None
11 12 13 14 15 16	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	17
	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	None
17 18 19	Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial _ participation	None
20 21 22 23	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	None
24 25		31b	Authorship eligibility guidelines and any intended use of professional writers	None
20 27 28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code _	None
29 30	Appendices			
31 32 33	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	None
34 35 36	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	None
37 38 39 40	*It is strongly recomm Amendments to the p " <u>Attribution-NonComm</u>	nended protoco <u>mercial</u>	I that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarificati I should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Com -NoDerivs 3.0 Unported" license.	on on the items. Imons
41 42 43 44 45 46 47			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	5

BMJ Open

Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2)

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-020785.R3
Article Type:	Protocol
Date Submitted by the Author:	09-Jul-2018
Complete List of Authors:	 Ai, Dashan; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Chen, Yun; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Liu, Qi; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhang, Junhua; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Deng, Jiaying; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Deng, Jiaying; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhu, Hanting; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Ren, Wenjia; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhu, Hanting; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Radiation Oncology Li, Yunhai; Fudan University Shanghai Cancer Center Minhang Branch Hospital, Department of Radiation Oncology Wei, Shihong; Gansu Province Cancer Hospital, Department of Radiation Oncology Ye, Jinjun; Jiangsu Cancer Hospital, Department of Radiation Oncology Lin, Qin; First Affiliated Hospital of Xiamen University, Department of Radiation Oncology Lin, Qin; First Affiliated Hospital of Xiamen University, Department of Radiation Oncology Lin, Jianchong; Shanxi Province Cancer Hospital, Department of R

	 Nuality, Guality, Halinan Province People's hospital, Department of Radiation Oncology Wu, Kailiang; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Fan, Min; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Yang, Huanjun; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhu, Zhengfei; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhu, Zhengfei; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Zhao, Weixin; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Li, Ling; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Li, Ling; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Oncology Fan, Jianhong; Renhe Hospital, Department of Gynecology Badakhshi, Harun; Charite ' School of Medicine and Centre for Cancer Medicine, Department of Radiation Oncology Zhao, Kuaile; Fudan University Shanghai Cancer Center, Department of Radiation Oncology; Shanghai Medical College, Fudan University, Department of Radiation Oncology
Primary Subject Heading :	Oncology
Secondary Subject Heading:	Oncology
Keywords:	esophageal squamous cell carcinoma, concurrent chemoradiotherapy,



Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2) Dashan Ai^{1, 2}, Yun Chen^{1, 2}, Qi Liu^{1, 2}, Junhua Zhang^{1, 2}, Jiaying Deng^{1, 2}, Hanting Zhu^{1, 2}, Wenjia Ren^{1, 2}, Xiangpeng Zheng³, Yunhai Li⁴, Shihong Wei⁵, Jinjun Ye⁶, Jialiang Zhou⁷, Qin Lin⁸, Hui Luo⁹, Jianzhong Cao¹⁰, Jiancheng Li¹¹, Guang Huang¹², Kailiang Wu^{1, 2}, Min Fan^{1, 2}, Huanjun Yang^{1, 2}, Zhengfei Zhu^{1, 2}, Weixin Zhao^{1, 2}, Ling Li^{1, 2}, Jianhong Fan¹³, Harun Badakhshi¹⁴, Kuaile Zhao^{1, 2} 1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China 3. Department of Radiation Oncology, Huadong Hospital Affiliated to Fudan University, Shanghai, China 4. Department of Radiation Oncology, Fudan University Shanghai Cancer Center Minhang Branch Hospital, Shanghai, China 5. Department of Radiation Oncology, Gansu Province Cancer Hospital, Lanzhou, China 6. Department of Radiation Oncology, Jiangsu Province Cancer Hospital, Nanjing, China 7. Department of Radiation Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China 8. Department of Radiation Oncology, First Affiliated Hospital of Xiamen University, Xiamen, China 9. Department of Radiation Oncology, Jiangxi Province Cancer Hospital, Nanchang, China 10. Department of Radiation Oncology, Shanxi Province Cancer Hospital, Taiyuan, China 11. Department of Thoracic Radiation Oncology, Fujian Province Cancer Hospital, Fuzhou, China 12. Department of Radiation Oncology, Hainan Province People's Hospital, Haikou, China

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

60

BMJ Open

1	
2	
4	13. Department of Gynecology, Renhe hospital, Shanghai, China
5	14. Department of Radiation Oncology, Charite' School of Medicine and Centre for
6 7	Cancer Medicine, Berlin, Germany
8	Corresponding author: Kuaile Zhao, 270 Dongan Rd, Shanghai, 200032, China. Email:
9 10	kuaile_z@shca.org.cn. Tel: +86-21-64175590
11	Key words: esophageal squamous cell carcinoma, concurrent chemoradiotherapy,
13	paclitaxel, cisplatin, carboplatin, fluorouracil
14	Word country 2 044 words
15	word counts: 5,044 words
16 17	
17	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30 21	
37	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
44	
45	
46	
47	
48	
49	
50	
51	
52 53	
55	
55	
56	
57	
58	2

Abstract

Introduction: Concurrent chemoradiation is the standard therapy for patients with local advanced esophageal carcinoma unsuitable for surgery. Paclitaxel is an active agent against esophageal cancer and it has been proved as a potent radiation sensitizer. There have been multiple studies evaluating paclitaxel-based chemoradiation in esophageal cancer, of which the results are inspiring. However, which regimen among cisplatin(TP), carboplatin(TC) or fluorouracil(TF) in combination with paclitaxel) concurrent with radiotherapy, provides best prognosis with minimum adverse events is still unknown and very few studies focus on this field. The purpose of this study is to confirm the priority of TF to TP or TC concurrent with radiotherapy in terms of overall survival and propose a feasible and effective plan for patients with local advanced esophageal cancer.

Methods and analysis: ESO-Shanghai 2 is a three-arm, multicenter, open-labeled, randomized phase III clinical trial. The study was initiated in July 2015 and the duration of inclusion is expected to be 4 years. The study compares two pairs of regimen: TF versus TP and TF versus TC concurrent with definitive radiotherapy for patients with esophageal squamous cell carcinoma (ESCC). Patients with histologically confirmed ESCC (clinical stage II, III or IVa based on the 6th UICC-TNM classification) and without any prior treatment of chemotherapy, radiotherapy or surgery against esophageal cancer will be eligible. A total of 321 patients will be randomized and allocated in a 1:1:1 ratio to the three treatment groups. Patients are stratified by lymph node status (N0, N1, M1a). The primary endpoint is overall survival and the secondary endpoint is progression-free survival and adverse events.

Ethics and dissemination:

This trial has been approved by the Fudan University Shanghai Cancer Center Institutional Review Board. Trial results will be disseminated via peer reviewed scientific journals and conference presentations.

Trial registration: Clinicaltrials.gov: NCT02459457

1 2 3 4 5	
6 7 8 9 10 11	
12 13 14 15 16 17	
18 19 20 21 22 23	
24 25 26 27 28 29	
30 31 32 33 34	
35 36 37 38 39 40	
41 42 43 44 45 46	
47 48 49 50 51	

59

60

Strengths and limitations of this study

- Strength This clinical trial is the first phase III randomized multi-centered study comparing these three regimens.
- Strength In the randomization session, patients were stratified by lymph node status (N0, N1, M1a based on the 6th UICC-TNM classification).

<text>

Introduction

Worldwide, esophageal cancer is the eighth most common cancer, which is responsible for an estimated 455,800 new cases and 400,200 deaths in 2012.¹ Since its prognosis is dismal, much effort has been put into improving overall survival through multi-modality treatments, which consist of surgery, radiotherapy and chemotherapy.² Concurrent chemoradiation is the standard non-operative therapy for local advanced esophageal squamous cell carcinoma (ESCC).³

Paclitaxel is an active agent against esophageal cancer, with the response rate of 28% in ESCC, and it has been shown to be a potent radiation sensitizer.⁴ There have been multiple studies evaluating paclitaxel-based chemoradiation in esophageal cancer, for instance, paclitaxel/fluorouracil (TF) developed at The University of Texas M.D. Anderson Cancer Center, and paclitaxel/cisplatin (TP) developed at Memorial Sloan-Kettering Cancer Center, ⁵⁶ with paclitaxel/carboplatin (TC) from CROSS trial.⁷ In many preoperative studies, paclitaxel-based chemoradiotherapy has achieved inspiring effects, the pathologic complete response rates of TP-based chemoradiotherapy were 19%-42%, ⁸⁻¹¹ and of TC-based chemoradiotherapy was 49%.⁷ However, which regimen, among TF, TP and TC-based definitive chemoradiotherapy, provides best prognosis with minimum adverse events is still unknown and very few studies focus on this field.

RTOG 0113⁵ evaluated 2 different paclitaxel-based regimens (TP and TF). Eighty-four patients were accrued to this study. Patients in arm A (TF) received induction 5-FU, cisplatin, and paclitaxel followed by radiation and concurrent continuous infusion 5-FU and weekly paclitaxel. Patients in arm B (TP) received induction paclitaxel and cisplatin followed by radiation and concurrent weekly cisplatin and 96-hour infusion of paclitaxel. The median survival time was 28.7 months for patients in arm A (TF) and 14.9 months for patients in arm B (TP). Neither arm achieved the hypothesized 1-year survival rate of at least 77.5%. The main deficiency of this study is the small sample size, but the effect of TF group is still inspiring.

Another retrospective multicenter randomize clinical trials from Europe¹² showed the overall survival of TC-based definitive chemoradiotherapy was comparable with cisplatin/5-FU (PF) as definitive concurrent chemoradiotherapy in

BMJ Open

esophageal cancer. However, the toxicity rates were lower in the TC group together with higher treatment compliance.

Based on RTOG 0113 and other reports, we designed a clinical trial to confirm the priority of TF to TP and TF to TC concurrent with definitive radiotherapy in terms of overall survival for patients with local advanced esophageal squamous cell carcinoma. The trial is a three-arm, multicenter, open-labeled, randomized phase III clinical trial.

Methods and analysis

Patient selection

To be eligible for this study, patient must fulfill all of the following criteria (Table 1):

Inclusion criteria

- 1. Histologically confirmed esophageal squamous cell carcinoma
- 2. Clinical stages II, III or IVa based on the 6th UICC-TNM classification
- 3. No prior treatments of chemotherapy, radiotherapy or surgery against esophageal cancer, except for non-curative resection by EMR/ESD.
- 4. Aged 18-75 years
- 5. Adequate organ functions for chemoradiation therapy
 - White blood cell (WBC) $\geq 3 \times 10^{9} L$ a)
 - Absolute neutrophil counts (ANC) $\geq 1.5 \times 10^{9}$ /L b)
 - Hemoglobin (Hb) ≥10g/dl c)
 - Platelet (Plt) $\geq 100 \times 10^{9}$ /L d)
 - 3/2 Total bilirubin <1.5 upper limit of normal (ULN) e)
 - Aspartate transaminase (AST) ≤2.5 ULN f)
 - Alanine aminotransferase (ALT) ≤2.5 ULN **g**)
 - h) Creatinine ≤ 1.5 ULN
- 6. ECOG PS of 0-2
- 7. Life expectancy \geq 3 months, based on the judgment of doctors
- 8. Written informed consent (Supplementary material)

Table 1. Inclusion criteria

Patients fulfilling any of the following criteria are ineligible for this study (Table 2).

Exclusion criteria

1. Esophageal perforation or hematemesis

2. Synchronous or metachronous malignancies (except for cutaneous (non-melanomas) carcinoma, thyroid papillary carcinoma, phase I seminoma or cervical carcinoma in situ curatively treated and disease free for a minimum of 3 months)

3. Received thoracic, abdominal or craniocerebral surgery within 30 days

4. Enrolled in other clinical trials within 30 days

5. Unstable angina and/or congestive heart failure requiring hospitalization within 6 months

6. Severe psychiatric disease

7. Pregnancy, lactation or unwillingness to adopt contraception

8. Drug addiction

9. Acquired immune deficiency syndrome (AIDS) based upon current CDC definition

10. History of radiotherapy in the planning area

11. Other ineligible conditions according to researchers

Table 2. Exclusion criteria

Treatment

The treatment plan is shown in Figure 1. Patients receive radiotherapy combined with concurrent chemotherapy. Radiotherapy begins on day 1, concurrent with the beginning of cycle 1 of chemotherapy.

Same radiation therapy will be delivered in all three treatment groups. According to current clinical practice in China, radiotherapy is delivered with photons (≥ 6 MV) to a total dose of 61.2Gy in 34 fractions. Patients will be treated 5 days per week at 1.8Gy/d. Three-dimensional conformal radiotherapy or intensity modulated radiotherapy is required. All patient will be positioned in an individualized immobilization device in the treatment position.

The definition of volumes will be in accordance with the 1993 ICRU Report #50 and 1999 ICRU Report #62.

The gross target volume (GTV) is defined as all known involved field, which

BMJ Open

detected by endoscopic ultrasound, barium swallow or CT scan (whichever is larger). The regional lymph nodes that have diameters more than 1cm (0.5cm for lymph nodes at tracheoesophageal groove) or that have been histologically proven metastatic after puncture are included in GTV.

The superior and inferior borders of the clinical target volume (CTV) are 3cm beyond the primary tumor along the esophagus. The lateral, anterior and posterior borders of the field are the same as GTV.

The superior, inferior, anterior, posterior and lateral borders of planning target volume (PTV) are 1cm beyond CTV. Field next to the spinal cord could be slightly adjusted in order to reduce the exposure of spinal cord.

As for target volume, tissue inhomogeneity correction is adopted and it is required that more than 99% PTV receive 95% prescription dose and more than 95% PTV receive 99% or more prescription dose. Highest and lowest point dose inside PTV should be recorded.

When making the treatment plan, we should take normal organ dose restrictions into consideration as the following order: (Table 3)

Risk organ	Contour regulation	Dose restriction
Spinal cord	All the layers of CT scan have	Highest point dose less
	to be contoured and the margin	than 45Gy
	of vertebra tube can be	
	regarded as that of planning	
	organ at risk volume.	
Lung	It is allowed to use automatic	The volume of lung (PTV
	tools in the delineation of	excluded) receiving 20Gy
	margin of lungs. (Trachea and	or higher has to be less
	bronchia must be contoured	than 30% of the total lung
	manually)	volume, and the mean
		dose has to be less than
		15Gy.
Heart	The superior margin of heart	The mean dose has to be
	consists of right atrium and	less than 40Gy.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

right ventricle, pulmonary artery trunk, ascending main aorta and superior vena cava excluded. The inferior margin is at the level of heart apex.

Table 3. Contour regulation and dose restriction of risk organs

Chemotherapy

Patients are randomly assigned to receive one of three therapies.

Arm A (TP)

Patients in arm A receive 4 courses of TP every 4 weeks. Details are as follows: Paclitaxel: 175mg/m²/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m²/d, ivgtt, d1-3;

Arm B (TF)

Patients in arm B receive 6 courses of TF concurrent with radiotherapy every week and 2 courses of TF consolidation chemotherapy every 4 weeks. Details are as follows:

Concurrent: paclitaxel 50mg/m²/d, ivgtt over 3 hours, d1; 5-FU 300mg/m², civ 96h, d1-4

Consolidation: paclitaxel 175 mg/m²/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m², civ 72h, d1-3

Arm C (TC)

Patients in arm C receive 6 courses of TC concurrent with radiotherapy every week and 2 courses of TC consolidation chemotherapy every 4 weeks. Details are as follows:

Concurrent: paclitaxel 50mg/m²/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1

Consolidation: paclitaxel 175 mg/m²/d, ivgtt over 3 hours, d1; carboplatin AUC=5, ivgtt, d1

Patients receive premedication to prevent allergic reaction and significant nausea or vomiting as indicated.

Dose modifications

Radiotherapy interruption

If following toxicity is observed, radiotherapy has to be delayed until toxicity is no more than grade 2.

- WBC<2.0×10⁹/L or ANC<1.0×10⁹/L
- $Plt < 50 \times 10^9/L$
- Grade 3 or higher non-hematological toxicity

If following toxicity is observed, radiotherapy has to be delayed until complete recovery.

• Mediastinal or thoracic infection with fever over 38.5

It is allowed to suspend at most 2 weeks, or radiotherapy will be terminated.

Chemotherapy interruption and dose modifications

If following toxicity is observed on day 1, chemotherapy has to be delayed until toxicity is no more than grade 1.

- ANC< 1.5×10^{9} /L
- $Plt < 100 \times 10^9/L$

• Grade 2 or higher non-hematological toxicity, except for nausea, vomiting and alopecia

It is allowed to delay at most 2 weeks, or chemotherapy will be terminated.

Chemotherapy dose modifications are based on the greatest toxicity during the last cycle. Any patients who need to make chemotherapy dose modifications will receive the modified dose in the following cycles.

If modifications are needed, dose of paclitaxel, cisplatin, carboplatin and 5-FU will decreased by 25% from the planned dose for the first time and 50% for the second time. It is allowed to make dose modifications at most twice, or chemotherapy will be terminated. Details are as follows:

Dose modification of paclitaxel

• Febrile neutropenia (ANC< 0.5×10^9 /L and fever over 38.3 or over 38.0 for 1h)

• Grade 2 or higher peripheral neuropathy

Dose modification of cisplatin and carboplatin

• Febrile neutropenia (ANC< 0.5×10^9 /L and fever over 38.3 or over 38.0 for 1h)

- Grade 2 or higher peripheral neuropathy
- Serum creatinine >3ULN

Dose modification of 5-FU

• Febrile neutropenia (ANC< 0.5×10^9 /L and fever over 38.3 or over 38.0 for

1h)

• Grade 3 or higher mucositis

The adverse events will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0). All adverse events, occurring during the course of the trial, which is from randomization until 28 days after end of treatment, regardless of relatedness to study medication, will be recorded. Adverse events occurring later than 28 days after the end of treatment will only be recorded if they are considered relevant.

Randomization

After the confirmation of eligibility criteria, patients will be randomly allocated in a 1:1:1 ratio to the three treatment groups by a central randomization center (Fudan University Shanghai Cancer Center, Shanghai, China). Patients will be stratified by lymph node status (N0, N1, M1a). The SAS was used to generate a random permutation sequence and produce patient randomization numbers. The data center registers the enrollment, assigns a unique identification number to every participant, and replies to the respective investigators.

Sample size calculation and statistical analysis

This three-arm randomized trial is designed to confirm whether TF is superior to TP or TC concurrent with radiotherapy in terms of overall survival. According to RTOG 0113 and other reports, median survival time of TF concurrent with radiotherapy for esophageal cancer is 28.7 months while TP 14.9 months⁵ and TC 17.4 months¹³. According to the Schoenfeld and Richter's method, the sample size of 107 patients per arm (154 events in total) is required to warrant a power of 80% at a

Page 13 of 29

BMJ Open

two-sided α level of 0.025 for the comparison between TP and TF with relatively smaller difference, assuming an accrual period of 48 months, a minimum follow-up period of 24 months and a dropout rate of $10\%^{14}$ ¹⁵. The total sample size is planned as 321 patients (107 patients in each arm, a total of 231 events).

The median overall survival will be estimated with Kaplan-Meier method, and log-rank test will be used to compare the overall survival among treatment arms. We will conduct a subgroup analyze to test whether the treatment effects differ among subgroups (N0, N1, M1a).

Endpoints

The primary endpoint is overall survival in all randomized patients. Overall survival is defined as time from the date of randomization until death. The secondary endpoint is progression free survival (PFS) and adverse events. PFS is defined as the time from the date of randomization to the date of progression or to the date of death, whichever occurs first and disease progression will be evaluated according to RECIST Version 1.1. Adverse events will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0).

Data collection

Participants will be seen at hospitals or contacted by telephone and letters from randomization to the last treatment cycle, then at Month 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54 and 60 after last treatment. Research staffs at the hospitals will be expected to complete trial CRFs.

Interim analysis

We plan to conduct two interim analyses. The first interim analysis will be conducted independently from the study group when half of the planned number of patients are enrolled and the second interim just after the planned patient accrual is completed. If the superiority of one of test arms (TF arm superior to TP arm or TC arm) is demonstrated with an adjusted α level, the study will be terminated.

In general, the interim reports will contain the following information:

1. Patient accrual rate with a projected completion date (while the study is still accruing)

2. Total patients accrued

3. Distributions of important pretreatment and prognostic baseline variables

4. The frequencies and severity of adverse events by treatment arm.

5. Compliance rates of treatment delivery

6. Observed results with respect to the primary and secondary endpoints

Patient and Public Involvement

Neither patients nor public will be involved in the design, recruitment, outcome measures and conduct of the study. Trial results will be disseminated via peer reviewed scientific journals and conference presentations rather than specifically notified to a single patient.

Ethics and dissemination

This trial has been approved by all participating centers including Fudan University Shanghai Cancer Center Institutional Review Board (Ethics Committee of Fudan University Shanghai Cancer Center: No.1505146-13). Written informed consent will be obtained from all participants. Serious adverse events will be reported to the safety desk of the trial, the Data and Safety Monitoring Board and trial sites. Trial results will be disseminated via peer reviewed scientific journals and conference presentations.

Participating institutions (From east to west)

Fudan University Shanghai Cancer Center, Huadong Hospital Affiliated to Fudan University, Fudan University Shanghai Cancer Center Minhang Branch, Affiliated Hospital of Jiangnan University, Fujian Province Cancer Hospital, Jiangsu Province Cancer Hospital, The First Affiliated Hospital of Xiamen University, Jiangxi Province Cancer Hospital, Shanxi Province Cancer Hospital, Hainan Province People's Hospital, Gansu Province Cancer Hospital

Trial Status

BMJ Open

2	
3	The trial was initiated in July 2015 and is currently recruiting patients in all of the
4	participating institutions above
5	participating institutions above.
7	
8	
9	
10	
11	Reference:
12	
13	1. Torre LA, Bray F, Siegel RL, et al. Global Cancer Statistics, 2012. Ca-Cancer J Clin
15	2015; 65 (2):87-108.
16	2 Enginger DC Mayor DI Ecophagoal cancer N Engl I Med
17	2. Elizinger PC, Mayer KJ. Esophagear cancel. N Eligi J Meu
18	2003; 349 (23):2241-52.
19	3. Herskovic A. Martz K. Alsarraf M. et al. Combined Chemotherapy and
20	
22	Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer
23	of the Esophagus. New Engl J Med 1992; 326 (24):1593-98.
24	A Ajani IA Ilson DH Daugharty K at al Activity of Tayol in Patients with
25	4. Ajam jA, iison DH, Daugherty K, et al. Activity of faxor in fatients with
20 27	Squamous-Cell Carcinoma and Adenocarcinoma of the Esophagus. J Natl
28	Cancer I 1994; 86 (14):1086-91.
29	5 Ajani IA Wintor K Komaki P at al Phase II randomized trial of two
30 31	5. Ajam jA, whiter K, Komaki K, et al. I hase if failed mized that of two
32	nonoperative regimens of induction chemotherapy followed by
33	chemoradiation in patients with localized carcinoma of the esophagus:
34	BTOG 0113 I Clin Oncol 2008- 26 (28)-4551-56
35 36	(Cabairan II, Kamalai P, Yao IC, at al Bilat atu du af ann annanat
37	6. Schnifer II, Komaki K, Yao JC, et al. Phot study of concurrent
38	5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of
39	the esophagus and gastroesophageal junction. Am I Clin Oncol-Canc
40 41	
42	2001; 24 (1):91-95.
43	7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant
44	chemoradiotherany plus surgery versus surgery alone for oesophageal or
45	enemorationerapy plus surgery versus surgery alone for besophagear of
40	junctional cancer (CROSS): long-term results of a randomised controlled
48	trial. Lancet Oncol 2015; 16 (9):1090-98.
49	8 Safran H. Caissort H. Alzarman P. at al. Paclitaval cigniatin and concurrent
50	o. Sanan n, Gaissert n, Akerman r, et al. racitaxei, cispiatin, and concurrent
51	radiation for esophageal cancer. Cancer Invest 2001; 19 (1):1-7.
53	9. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative
54	
55	combined-modality therapy for localized esophageal carcinoma: Initial
56	results. J Thorac Cardiov Sur 2002; 124 (2):270-77.
57 58	
59	14

10. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;**98**(10):2177-83.

- 11. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18(1):93-98.
- 12. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;**25**(3):638-43.
- 13. Mohammad NH, Hulshof MCCM, Bergman JJGHM, et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. Bmc Cancer 2014;**14**.
- 14. Lakatos E. Designing complex group sequential survival trials. Stat Med 2002;**21**(14):1969-89.
- 15. Lakatos E. Sample Sizes Based on the Log-Rank Statistic in Complex Clinical-Trials. Biometrics 1988;44(1):229-41.

59

2	
3	Declarations
4 5	List of abbreviations
6	TP: Paclitaxel combined with cisplatin
8	TC: Paclitaxel combined with carbonlatin
9	
10 11	IF: Pachtaxel combined with fluorouracii
12	UICC: Union for International Cancer Control
13	ESCC: Esophageal squamous cell carcinoma
14	PF: Cisplatin combined with fluorouracil
16	AIDS: Acquired immune deficiency syndrome
18	RT: Radiotherapy
19 20	PTX: Paclitaxel
21	DDP: Cisplatin
22	CBP: Carbonlatin
24	
25	5-FU: Fluorouracil
27	W: Week
28	ICRU: International Commission on Radiation Units and Measurements
30	GTV: Gross Target Volume
31	CTV: Clinical Target Volume
33	PTV: Planning Target Volume
34 35	WBC: White Blood Cell
36	ANC: Absolute Neutrophil Counts
37 38	Hb: Hemoglobin
39	Plt: Platelet
40 41	HI N. Hanna Lineit of Normal
42	OLN: Opper Limit of Normal
43	AST: Aspartate Transaminase
45	ALT: Alanine aminotransferase
46	
47 48	
49	
50	Consent of publication
51	Not applicable
53	
54	Declaration of interests
55	
50 57	We declare no competing interests.
58	

Funding

The study was supported by 2015 Prospective Clinical Research Fund of Fudan University Shanghai Cancer Center.

Author's contributions

D Ai was responsible for drafting the manuscript. Y Chen, Q Liu, J Zhang, J Deng, H Zhu, W Ren, K Wu, M Fan, H Yang, Z Zhu, W Zhao, L Li were responsible for the collection of previous study and putting forward the conception. X Zheng, Y Li, J Ye, J Zhou, Q Lin, H Luo, J Cao, S Wei, J Fan, J Li, G Huang and H Badakhshi were responsible for designing the details of the study. K Zhao was responsible for all aspects of trial design, the protocol and trial conduct. All authors have read and approved this manuscript.

Data Sharing Statement

No additional unpublished data from the study are available.

1	
2	
3 4	Fig1. Treatment Design of the ESO-Shanghai 2 trial.
5	TP (arm A), TF (arm B) and TC (arm C) are TP-, TF- and TC-based definitive
6 7	chemoradiotherapy, respectively.
8	RT=radiotherapy, PTX=paclitaxel, DDP=cisplatin, 5-Fu=fluorouracil,
9	CBP=carbonlatin W=Week
10	
12	
13	
15	
16	
17 18	
19	
20	
21 22	
23	
24	
26	
27	
28 29	
30	
31	
33	
34	
35 36	
37	
38 30	
40	
41	
42 43	
44	
45 46	
47	
48	
49 50	
51	
52 53	
54	
55	
סס 57	
58	
59 60	For peer review only - http://bmjopen.bmi.com/site/about/auidelines.xhtml
00	



Fig1. Treatment design of the ESO-Shanghai 2 trial. $| \top | RT$ =radiotherapy, PTX=paclitaxel, DDP=cisplatin, 5-Fu=fluorouracil, CBP=carboplatin, W=Week. $| \top |$

80x56mm (300 x 300 DPI)

Informed Consent Form

Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2)

You are being asked to take part in a clinical study. Please take your time to make your decision about taking part. If you have any questions, you can ask your study doctor for more explanation.

You are being asked to take part in this study because you have local advanced esophageal squamous cell carcinoma.

Why is this study being done?

Concurrent chemoradiation is the standard therapy for patients with local advanced esophageal carcinoma unsuitable for surgery. Paclitaxel is an active agent against esophageal cancer and it has been proved as a potent radiation sensitizer. There have been multiple studies evaluating paclitaxel-based chemoradiation in esophageal cancer, the results of which are inspiring. However, which regimen, among paclitaxel in combination with cisplatin (TP), carboplatin (TC) and fluorouracil (TF) concurrent with radiotherapy, provides best prognosis with minimum adverse events is still considered far from resolved and very few studies focus on this field. The purpose of this study is to confirm the priority of TF to TP or TC concurrent with radiotherapy in terms of overall survival and propose a feasible and effective plan for patients with local advanced esophageal cancer.

How many people will take part in the study?

About 321 people will take part in this study.

What will happen if I take part in this research study?

You will be randomized and allocated in a 1:1:1 ratio to the three treatment groups (TF, TP or TC). You will receive radiotherapy combined with concurrent chemotherapy. Radiotherapy will begin on day 1, concurrent with the beginning of cycle 1 of chemotherapy.

Radiation therapy

Same radiation therapy will be delivered in all three treatment groups. Radiotherapy will be delivered with photons (≥6 MV) to a total dose of 61.2Gy in 34 fractions. You will be treated 5 days per week at 1.8Gy/d.

Chemotherapy

Arm A (TP)

If you are in arm A, you will receive 4 courses of TP every 4 weeks. Details are as follows:

Paclitaxel: 175mg/m²/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m²/d, ivgtt, d1-3; Arm B (TF)

If you are in arm B, you will receive 6 courses of TF concurrent with radiotherapy every week and 2 courses of TF adjuvant chemotherapy every 4 weeks. Details are as follows:

Concurrent: paclitaxel 50mg/m²/d, ivgtt over 3 hours, d1; 5-FU 300mg/m², civ 96h, d1-4

Adjuvant: paclitaxel 175 mg/m²/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m², civ 72h,

d1-3

Arm C (TC)

If you are in arm C, you will receive 6 courses of TC concurrent with radiotherapy every week and 2 courses of TC adjuvant chemotherapy every 4 weeks. Details are as follows:

Concurrent: paclitaxel 50mg/m²/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1 Adjuvant: paclitaxel 175 mg/m²/d, ivgtt over 3 hours, d1; carboplatin AUC=5, ivgtt, d1

During each treatment, blood tests will be performed to monitor blood counts, kidney function, liver function and electrolyte levels. Ultrasound, barium swallow and CT scan with contrast will be performed to evaluate the status of disease.

How long will I be in the study?

After your treatment is completed, you will be seen in follow-up visits with your doctor every 3 months in years 1-2, every 6 months in years 3-5 and then once a year for your lifetime.

Can I stop being in the study?

Yes. You can decide to stop at any time. Tell the study doctor if you are thinking about stopping or decide to stop. He or she will tell you how to stop safely.

It is important to tell the study doctor if you are thinking about stopping so he or she can evaluate any risks from the treatment. Another reason to tell your study doctor that you are thinking about stopping is to discuss what follow-up care and testing could be most helpful for you.

The study doctor may stop you from taking part in this study at any time if he/she believes it is in your best interest, if you do not follow the study rules, or if the study is stopped.

What side effects or risks can I expect from being in the study?

You may have side effects while on the study. Everyone taking part in the study will be watched carefully for any side effects. However, doctors don't know all the side effects that may happen. Side effects may be mild or very serious. There also is a risk of death.

Risks and side effects related to the chemoradiotherapy

- Soreness in throat or esophagus
- Cough
- Vomiting
- Nausea
- Fatigue
- Anorexia (loss of appetite)
- Diarrhea
- Numbness in arms and legs
- Allergic reaction
- Hair loss
- Redness of irritation of the skin in the treatment area
- Decrease in white blood cell counts and high risk of infection
- Renal insufficiency,

Are there benefits to taking part in the study?

Taking part in this study may or may not make your health better. While researchers hope these treatment regimens will be more useful against cancer compared to the usual treatment, there is no proof of this yet. We do know that the information from this study will help researchers learn more about these combinations of drugs as a treatment for cancer. This information could help future cancer patients.

Will my medical information be kept private?

We will do our best to make sure that the personal information in your medical record will be kept private. Your personal information may be given out if required by law. If information from this study is published or presented at scientific meetings, your name and other personal information will not be used.

What happens if I am injured because I took part in this study?

It is important that you tell your study doctor if you feel that you have been injured because of taking part in this study. You will get medical treatment if you are injured as a result of taking part in this study. You and/or your health plan will be charged for this treatment. The study will not pay for medical treatment.

What are my rights if I take part in this study?

Taking part in this study is your choice. You may choose either to take part or not to take part in the study. If you decide to take part in this study, you may leave the study at any time. No matter what decision you make, there will be no penalty to you and you will not lose any of your regular benefits. Leaving the study will not affect your medical care. You can still get your medical care from our center.

We will tell you about new information or changes in the study that may affect your health or your willingness to continue in the study.

In the case of injury resulting from this study, you do not lose any of your legal rights to seek payment by signing this form.

WHO CAN ANSWER MY QUESTIONS ABOUT THE STUDY?

You can talk to your study doctor about any questions or concerns you have about this study. Contact your study doctor, Kuaile Zhao, at 021-64175590.

Signature

I have been given a copy of all 5 pages of this form. I have read it or it has been read to me. I understand the information and have had my questions answered. I agree to take part in this study.

Participant:		
Name of Participant	Signature	Date
Researcher:	í ez	0
Name of Participant	Signature	Date



45 46 47

SPIRIT STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Administrative information Title 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym 1 Trial registration 2a Trial identifier and registry name. If not yet registered, name of intended registry 3 2b All items from the World Health Organization Trial Registration Data Set	sed on umber
Title 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym 1 Trial registration 2a Trial identifier and registry name. If not yet registered, name of intended registry 3 2b All items from the World Health Organization Trial Registration Data Set	
Trial registration 2a Trial identifier and registry name. If not yet registered, name of intended registry 3 2b All items from the World Health Organization Trial Registration Data Set Nor Protocol version 3 Date and version identifier Nor Funding 4 Sources and types of financial, material, and other support 1^1 Roles and responsibilities 5a Names, affiliations, and roles of protocol contributors 1^1 Sources and types of financial, material sponsor 1^1 Roles and responsibilities 5b Name and contact information for the trial sponsor Nor 5c Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	
2b All items from the World Health Organization Trial Registration Data Set	
Protocol version 3 Date and version identifier	e
Funding 4 Sources and types of financial, material, and other support 1^1 Roles and 5a Names, affiliations, and roles of protocol contributors 1^1 responsibilities 5b Name and contact information for the trial sponsor Nor 5c Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities Nor 5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint Nor	ie
Roles and 5a Names, affiliations, and roles of protocol contributors 1^* responsibilities 5b Name and contact information for the trial sponsor Nor 5b Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities Nor 5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint Nor	·
responsibilities 5b Name and contact information for the trial sponsor Nor 5c Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities Nor 5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint Nor	,
 5c Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including Nor whether they will have ultimate authority over any of these activities 5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint Nor 	ie
5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint Nor	e
adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	e

1 2					
$\begin{array}{c} 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\end{array}$	Introduction				
	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant	5	
		6b	Explanation for choice of comparators	6	
	Objectives	7	Specific objectives or hypotheses	6	
	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6	
	Methods: Participants, interventions, and outcomes				
	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will _ be collected. Reference to where list of study sites can be obtained	13	
	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	6-7	
	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be _ administered	7-9	
		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose _ change in response to harms, participant request, or improving/worsening disease)	10	
		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	None	
		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	9	
	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, _ median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	12	
	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for _ participants. A schematic diagram is highly recommended (see Figure)	13	
			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	2	

2 3 4	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	_11-12	
5 6 7	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	_None	
8	Methods: Assignm	ent of ir	nterventions (for controlled trials)		
9 10	Allocation:				
11 12 13 14 15 16	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	_11	
17 18 19 20	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered,	_11	
21 22 23	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to	_11	
24 25 26	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	_ None	
27 28 29 30		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	_ None	
31 32	Methods: Data coll	ection,	management, and analysis		
33 34 35 36 37	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_ 11	
38 39 40		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	_ 12	
42 43 44 45 46 47			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		3

1 ว				
2 3 4 5	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality _ (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	None
6 7 8	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the _ statistical analysis plan can be found, if not in the protocol	12
9 10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	12
11 12 13 14		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	None
15 16	Methods: Monitorin	ıg		
17 18 19 20 21	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of _ whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	None
22 23 24		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim _ results and make the final decision to terminate the trial	12-13
25 26 27	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	11
28 29 30	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	None
31 32	Ethics and dissemi	nation		
33 34 35 36	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	13
37 38 39 40 41 42	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes,analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	None
43 44 45 46 47			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	4

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	None
		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	None
	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	None
	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	17
	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	None
	Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	None
	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	None
24 25		31b	Authorship eligibility guidelines and any intended use of professional writers	None
26 27 28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	None
29 30	Appendices			
31 32 33 34 35 36 37 38 39 40	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Supplementary
	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	None
	*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons " <u>Attribution-NonCommercial-NoDerivs 3.0 Unported</u> " license.			
41 42 43				5
44 45 46 47			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	